[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 969
1. Mostert S, Sitaresmi MN, Gundy CM, Sutaryo, Veerman AJ: Parental experiences of childhood leukemia treatment in indonesia. J Pediatr Hematol Oncol; 2008 Oct;30(10):738-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parental experiences of childhood leukemia treatment in indonesia.
  • In our study, we examined socioeconomic, treatment-related, and psychologic experiences of parents during the acute lymphoblastic leukemia treatment of their children in an academic hospital in Indonesia.
  • Parents lost their jobs (29% of fathers and 8% of mothers), most of whom stated that this loss of employment was caused by the leukemia of their child (87% of fathers and 100% of mothers).
  • We have concluded that the socioeconomic impact of leukemia treatment was profound.
  • [MeSH-major] Leukemia / psychology. Parents / psychology. Socioeconomic Factors

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011470.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


2. Stam RW, Den Boer ML, Schneider P, de Boer J, Hagelstein J, Valsecchi MG, de Lorenzo P, Sallan SE, Brady HJ, Armstrong SA, Pieters R: Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. Blood; 2010 Feb 4;115(5):1018-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
  • MLL-rearranged acute lymphoblastic leukemia (ALL) represents an unfavorable type of leukemia that often is highly resistant to glucocorticoids such as prednisone and dexamethasone.
  • Because response to prednisone largely determines clinical outcome of pediatric patients with ALL, overcoming resistance to this drug may be an important step toward improving prognosis.
  • Here, we show how gene expression profiling identifies high-level MCL-1 expression to be associated with prednisolone resistance in MLL-rearranged infant ALL, as well as in more favorable types of childhood ALL.
  • To validate this observation, we determined MCL-1 expression with quantitative reverse transcription-polymerase chain reaction in a cohort of MLL-rearranged infant ALL and pediatric noninfant ALL samples and confirmed that high-level MCL-1 expression is associated with prednisolone resistance in vitro.
  • Finally, down-regulation of MCL-1 in prednisolone-resistant MLL-rearranged leukemia cells by RNA interference, to some extent, led to prednisolone sensitization.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Prednisone / pharmacology. Proto-Oncogene Proteins c-bcl-2 / genetics
  • [MeSH-minor] Cell Survival / drug effects. Child. Gene Expression Profiling. Gene Expression Regulation, Leukemic. Gene Rearrangement. Glucocorticoids / pharmacology. Glucocorticoids / therapeutic use. Histone-Lysine N-Methyltransferase. Humans. Immunoblotting. Infant. Myeloid Cell Leukemia Sequence 1 Protein. Oligonucleotide Array Sequence Analysis. RNA Interference. Reverse Transcriptase Polymerase Chain Reaction


3. Bhushan B, Chauhan PS, Saluja S, Verma S, Mishra AK, Siddiqui S, Kapur S: Aberrant phenotypes in childhood and adult acute leukemia and its association with adverse prognostic factors and clinical outcome. Clin Exp Med; 2010 Mar;10(1):33-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant phenotypes in childhood and adult acute leukemia and its association with adverse prognostic factors and clinical outcome.
  • Occurrence of aberrant phenotypes in childhood and adult acute leukemia (AL) differs considerably in independent studies and their association with prognostic factors is still controversial.
  • In AML, aberrant expression of CD19 was expressed in 52 and 32% while CD7 was expressed in 14 and 15% cases of childhood and adult AML, respectively.
  • In summary, aberrant phenotype was commonly seen in adults than childhood B-ALL while in AML, aberrant phenotype was more common in children than adults.
  • CD19 was most commonly expressed antigen followed by CD7 in both childhood and adult AML.
  • Interestingly, aberrant phenotype was not found in childhood T-ALL; however, it was seen in 33% cases of adults.
  • We did not find any association of aberrant phenotype with adverse prognosis factors, CD34 marker, and clinical outcome except the absence of auer rod which was found to be significantly associated with aberrant phenotype of childhood AML (P = 0.01).
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 1997 Jan-Feb;82(1):31-7 [9107079.001]
  • [Cites] Pediatr Hematol Oncol. 1995 Sep-Oct;12(5):463-9 [8519631.001]
  • [Cites] Leuk Lymphoma. 2001 Jun;42(1-2):75-82 [11699224.001]
  • [Cites] N Engl J Med. 1991 Mar 21;324(12):800-8 [1997852.001]
  • [Cites] N Engl J Med. 1987 Apr 30;316(18):1111-7 [3494942.001]
  • [Cites] Cytometry B Clin Cytom. 2008 Jan;74(1):25-9 [18061959.001]
  • [Cites] Exp Mol Pathol. 2007 Dec;83(3):462-3 [17927977.001]
  • [Cites] Ann Hematol. 1995 Apr;70(4):189-94 [7748963.001]
  • [Cites] Blood. 1993 May 1;81(9):2399-405 [7683218.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1564-70 [8635059.001]
  • [Cites] J Trop Pediatr. 2000 Apr;46(2):73-8 [10822932.001]
  • [Cites] Blood. 1993 Jul 15;82(2):343-62 [8329694.001]
  • [Cites] Am J Hematol. 1998 Aug;58(4):278-84 [9692390.001]
  • [Cites] Blood. 1988 Aug;72(2):579-87 [3261183.001]
  • [Cites] J Clin Oncol. 1990 Aug;8(8):1389-98 [1696310.001]
  • [Cites] Blood. 1992 Nov 15;80(10):2471-8 [1421370.001]
  • [Cites] Blood. 1991 Sep 1;78(5):1327-37 [1878594.001]
  • [Cites] Blood. 1995 Oct 15;86(8):3097-108 [7579404.001]
  • [Cites] Blood. 1991 May 15;77(10):2242-50 [1709379.001]
  • [Cites] Am J Clin Pathol. 1998 Feb;109(2):211-20 [9583894.001]
  • [Cites] Blood. 2000 Aug 1;96(3):870-7 [10910899.001]
  • [Cites] Leukemia. 1994 Mar;8(3):388-94 [7907393.001]
  • [Cites] Haematologica. 2001 Aug;86(8):801-6 [11522535.001]
  • [Cites] Blood. 1992 Jul 15;80(2):470-7 [1378322.001]
  • [Cites] Exp Mol Pathol. 2007 Dec;83(3):471-3 [17963747.001]
  • [Cites] Blood. 1993 Aug 1;82(3):889-94 [7687897.001]
  • [Cites] J Exp Clin Cancer Res. 2007 Sep;26(3):313-21 [17987789.001]
  • [Cites] Leukemia. 1991 Aug;5(8):637-45 [1886419.001]
  • [Cites] Exp Mol Pathol. 2005 Aug;79(1):39-41 [16005710.001]
  • [Cites] Leukemia. 1993 Apr;7(4):489-98 [7681917.001]
  • [Cites] J Egypt Natl Canc Inst. 2006 Sep;18(3):244-9 [17671534.001]
  • [Cites] Ann Hematol. 2002 Sep;81(9):498-503 [12373349.001]
  • [Cites] Blood. 1992 May 1;79(9):2415-22 [1571553.001]
  • [Cites] Br J Haematol. 1989 Dec;73(4):480-5 [2482063.001]
  • [Cites] Zhonghua Er Ke Za Zhi. 2003 May;41(5):334-7 [14751050.001]
  • [Cites] Blood. 1997 Jul 1;90(1):28-35 [9207434.001]
  • [Cites] Leuk Res. 1990;14(1):23-6 [1689436.001]
  • [Cites] Blood. 1991 Sep 1;78(5):1292-300 [1715222.001]
  • [Cites] Blood. 1983 Jun;61(6):1138-45 [6404327.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1419-29 [1517785.001]
  • [Cites] Leukemia. 1994 Dec;8(12):2118-26 [7807999.001]
  • [Cites] Hua Xi Yi Ke Da Xue Xue Bao. 2002 Jan;33(1):118-20 [12599447.001]
  • [Cites] Blood. 1993 Jun 1;81(11):3083-90 [8499643.001]
  • [Cites] Haematologica. 2007 Mar;92(3):342-8 [17339183.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):380-9 [11888077.001]
  • (PMID = 19779962.001).
  • [ISSN] 1591-9528
  • [Journal-full-title] Clinical and experimental medicine
  • [ISO-abbreviation] Clin. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


Advertisement
4. Maloney KW, Carroll WL, Carroll AJ, Devidas M, Borowitz MJ, Martin PL, Pullen J, Whitlock JA, Willman CL, Winick NJ, Camitta BM, Hunger SP: Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. Blood; 2010 Aug 19;116(7):1045-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group.
  • Children with Down syndrome (DS) have an increased risk of acute lymphoblastic leukemia (ALL) and an inferior outcome.
  • We reviewed data from 2811 children with ALL enrolled in Children's Oncology Group P9900, which included prospective testing for the major cytogenetic lesions in childhood ALL: ETV6-RUNX1, TCF3-PBX1, BCR-ABL1, and MLL translocations and trisomies of chromosomes 4 and 10.
  • Age, sex, white blood cell count, and risk group were similar between DS-ALL and non-DS-ALL but significantly more patients with DS-ALL were white (91.2% vs 76.4%, P = .001).

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2008 Aug 1;113(3):515-21 [18521927.001]
  • [Cites] Arch Dis Child. 2001 Oct;85(4):321-5 [11567943.001]
  • [Cites] Br J Haematol. 2000 Sep;110(3):512-24 [10997960.001]
  • [Cites] J Pediatr. 1984 Aug;105(2):235-42 [6235337.001]
  • [Cites] Arch Dis Child. 1990 Feb;65(2):212-6 [2138446.001]
  • [Cites] Cancer. 1991 Feb 15;67(4):1057-63 [1825025.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1361-7 [8315434.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):18-24 [8558195.001]
  • [Cites] Leukemia. 1998 May;12(5):645-51 [9593260.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1663-71 [9614257.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):21-8 [15368546.001]
  • [Cites] Br J Haematol. 2005 Mar;128(6):797-804 [15755283.001]
  • [Cites] Leukemia. 2005 May;19(5):734-40 [15789069.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4043-9 [16109782.001]
  • [Cites] Br J Haematol. 2006 Dec;135(5):595-602 [17054672.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1575-83 [17971484.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5477-85 [18388178.001]
  • [Cites] Lancet. 2008 Oct 25;372(9648):1484-92 [18805579.001]
  • [Cites] Blood. 2009 Jan 15;113(3):646-8 [18927438.001]
  • [Cites] Br J Haematol. 2009 Mar;144(6):930-2 [19120350.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9414-8 [19470474.001]
  • [Cites] Nat Genet. 2009 Nov;41(11):1243-6 [19838194.001]
  • [Cites] Blood. 2010 Feb 4;115(5):1006-17 [19965641.001]
  • [Cites] Blood. 2010 Jul 1;115(26):5312-21 [20139093.001]
  • [CommentIn] Blood. 2010 Aug 19;116(7):1019-20 [20724545.001]
  • (PMID = 20442364.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / CA114766; United States / NCI NIH HHS / CA / U24 CA114766; United States / NCI NIH HHS / CA / CA086011; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / R01 CA086011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / MLL protein, human; 0 / Oncogene Proteins, Fusion; 0 / TCF3-PBX1 fusion protein, human; 0 / TEL-AML1 fusion protein; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Other-IDs] NLM/ PMC2938126
  •  go-up   go-down


5. McNally RJ, Eden TO, Alexander FE, Kelsey AM, Birch JM: Is there a common aetiology for certain childhood malignancies? Results of cross-space-time clustering analyses. Eur J Cancer; 2005 Dec;41(18):2911-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a common aetiology for certain childhood malignancies? Results of cross-space-time clustering analyses.
  • We previously demonstrated significant space-time clustering amongst cases of childhood leukaemia (in particular acute lymphoblastic leukaemia (ALL)), central nervous system (CNS) tumour (especially astrocytoma), soft tissue sarcoma and Wilms' tumour.
  • There was no statistically significant cross-clustering of Wilms' tumours and soft tissue sarcomas with any other malignancy.
  • In conclusion, these findings are consistent with common, possibly infectious, aetiological mechanisms for childhood leukaemia (particularly ALL) and CNS tumours (particularly astrocytoma).
  • [MeSH-minor] Adolescent. Astrocytoma / epidemiology. Astrocytoma / etiology. Central Nervous System Neoplasms / epidemiology. Central Nervous System Neoplasms / etiology. Child. Child, Preschool. England / epidemiology. Environment. Humans. Incidence. Infant. Infant, Newborn. Infection. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Residence Characteristics. Sarcoma / epidemiology. Sarcoma / etiology. Space-Time Clustering. Wilms Tumor / epidemiology. Wilms Tumor / etiology

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16243517.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


6. Lauten M, Fernandez-Munoz I, Gerdes K, von Neuhoff N, Welte K, Schlegelberger B, Schrappe M, Beger C: Kinetics of the in vivo expression of glucocorticoid receptor splice variants during prednisone treatment in childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer; 2009 Apr;52(4):459-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kinetics of the in vivo expression of glucocorticoid receptor splice variants during prednisone treatment in childhood acute lymphoblastic leukaemia.
  • BACKGROUND: The in vivo glucocorticoid response in childhood acute lymphoblastic leukaemia (ALL) correlates with the response to multi-agent chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Gene Expression / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Prednisone / therapeutic use. Receptors, Glucocorticoid / biosynthesis

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • (PMID = 19061214.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Protein Isoforms; 0 / Receptors, Glucocorticoid; VB0R961HZT / Prednisone
  •  go-up   go-down


7. Troeger A, Gudowius S, Escherich G, den Boer ML, Glouchkova L, Ackermann B, Meisel R, Laws HJ, Groeger M, Wessalowski R, Willers R, Harbott J, Pieters R, Goebel U, Janka-Schaub GE, Hanenberg H, Dilloo D: High nerve growth factor receptor (p75NTR) expression is a favourable prognostic factor in paediatric B cell precursor-acute lymphoblastic leukaemia. Br J Haematol; 2007 Nov;139(3):450-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High nerve growth factor receptor (p75NTR) expression is a favourable prognostic factor in paediatric B cell precursor-acute lymphoblastic leukaemia.
  • In spite of its established role in B-cell function and identification as a prognostically favourable marker in a number of malignancies, little is known about the expression pattern and prognostic significance of p75NTR in B cell precursor-acute lymphoblastic leukaemia (BCP-ALL).
  • p75NTR expression was prospectively studied on primary ALL-blasts in a cohort of paediatric patients with common ALL (n = 86) and preB-ALL (n = 34) treated within the Co-operative study group for childhood acute lymphoblastic leukaemia (CoALL) protocol, CoALL06-97.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Nerve Tissue Proteins / blood. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / blood. Receptors, Nerve Growth Factor / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17910636.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NGFR protein, human; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / Receptors, Nerve Growth Factor
  •  go-up   go-down


8. Dorak MT, Mackay RK, Relton CL, Worwood M, Parker L, Hall AG: Hereditary hemochromatosis gene (HFE) variants are associated with birth weight and childhood leukemia risk. Pediatr Blood Cancer; 2009 Dec 15;53(7):1242-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hereditary hemochromatosis gene (HFE) variants are associated with birth weight and childhood leukemia risk.
  • BACKGROUND: Our original studies reported an association between the iron-metabolism gene HFE and risk of childhood acute lymphoblastic leukemia (ALL), and a birth weight association in ALL.
  • We hypothesize that HFE links higher infant birth weight with leukemia risk and that maternal HFE genotype modifies this association.
  • PROCEDURE: Nine hundred ninety-five infants and their mothers from the North Cumbria Community Genetics Project, and 163 incident childhood ALL cases from the Newcastle Haematology Biobank were genotyped for HFE, HAMP, TFRC variants and 21 genomic control loci.
  • [MeSH-major] Antigens, CD / genetics. Antimicrobial Cationic Peptides / genetics. Birth Weight / genetics. Hemochromatosis / genetics. Histocompatibility Antigens Class I / genetics. Infant, Low Birth Weight. Membrane Proteins / genetics. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Pregnancy Complications / genetics. Receptors, Transferrin / genetics


9. Guo Y, Fan BL, Chen YM, Hu Y, Zou Y, Chen XJ, Zhang L, Zhu XF: [Mass spectrography analysis of differential proteome in childhood TEL/AML1-positive acute lymphoblastic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb;18(1):116-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mass spectrography analysis of differential proteome in childhood TEL/AML1-positive acute lymphoblastic leukemia].
  • The study was aimed to establish differential proteomic expression analysis of two dimensional electrophoresis and mass spectrography, and to further explore the mechanisms of nosogenesis in childhood TEL/AML1(+) acute lymphoblastic leukemia.
  • The results showed that the significant difference of protein expression profile existed in 3 groups of childhood TEL/AML1-positive acute lymphoblastic leukemia.
  • Some proteins may be further used in research on leukemia mechanisms.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137130.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / Proteome; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


10. Follin C, Thilén U, Ahrén B, Erfurth EM: Improvement in cardiac systolic function and reduced prevalence of metabolic syndrome after two years of growth hormone (GH) treatment in GH-deficient adult survivors of childhood-onset acute lymphoblastic leukemia. J Clin Endocrinol Metab; 2006 May;91(5):1872-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement in cardiac systolic function and reduced prevalence of metabolic syndrome after two years of growth hormone (GH) treatment in GH-deficient adult survivors of childhood-onset acute lymphoblastic leukemia.
  • CONTEXT: Survivors of childhood-onset (CO) acute lymphoblastic leukemia (ALL) treated with prophylactic cranial radiotherapy often exhibit GH deficiency (GHD), which is associated with increased prevalence of cardiovascular risk factors and cardiac dysfunction.
  • [MeSH-major] Growth Hormone / therapeutic use. Heart / physiology. Human Growth Hormone / deficiency. Metabolic Syndrome X / prevention & control. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • MedlinePlus Health Information. consumer health - Metabolic Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16522695.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin; 0 / Lipoproteins; 12629-01-5 / Human Growth Hormone; 9002-72-6 / Growth Hormone
  •  go-up   go-down


11. Ning F, Cai SJ, Zhang TJ, Liu XX, Zhang YM: [Expression of nm23 H(1) gene in childhood acute lymphoblastic leukemia and the relationship between nm23 H(1) expression and immunophenotype]. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Nov;11(11):881-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of nm23 H(1) gene in childhood acute lymphoblastic leukemia and the relationship between nm23 H(1) expression and immunophenotype].
  • OBJECTIVE: To study the expression of nm23-H(1) gene in children with acute lymphoblastic leukemia (ALL) and the relationship between nm23-H(1) expression and immunophenotype.
  • [MeSH-major] NM23 Nucleoside Diphosphate Kinases / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


12. Matsuzaki A, Nagatoshi Y, Inada H, Nakayama H, Yanai F, Ayukawa H, Kawakami K, Moritake H, Suminoe A, Okamura J: Prognostic factors for relapsed childhood acute lymphoblastic leukemia: impact of allogeneic stem cell transplantation--a report from the Kyushu-Yamaguchi Children's Cancer Study Group. Pediatr Blood Cancer; 2005 Aug;45(2):111-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for relapsed childhood acute lymphoblastic leukemia: impact of allogeneic stem cell transplantation--a report from the Kyushu-Yamaguchi Children's Cancer Study Group.
  • BACKGROUND: The treatment results of childhood acute lymphoblastic leukemia (ALL) with a first relapse were retrospectively analyzed to determine prognostic factors.
  • The potential prognostic factors examined were: the time of initial diagnosis, gender, immunophenotype of leukemic blasts and the NCI-risk classification at initial diagnosis, the site of relapse, the time of relapse (early: within 18 months after diagnosis, intermediate: other than either early or late relapse, late: later than 6 months after the discontinuation of front-line chemotherapy), and the treatment after relapse (chemotherapy alone and SCT).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation


13. Lyu CJ, Rha SY, Won SC: Clinical role of bone marrow angiogenesis in childhood acute lymphocytic leukemia. Yonsei Med J; 2007 Apr 30;48(2):171-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical role of bone marrow angiogenesis in childhood acute lymphocytic leukemia.
  • But, until today, the importance of theses factors on leukemia, especially childhood acute lymphocytic leukemia (ALL) has received limited attention.
  • CONCLUSION: Our data suggest that the increased levels of VEGF and bFGF in bone marrow may play an important role in prognosis of childhood ALL.
  • [MeSH-major] Bone Marrow / blood supply. Neovascularization, Pathologic / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jan 1;95(1):309-13 [10607717.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4303-7 [16123221.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2240-5 [10979972.001]
  • [Cites] Leuk Lymphoma. 2001 Jun;42(1-2):83-8 [11699225.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3381-4 [11705851.001]
  • [Cites] Leuk Lymphoma. 2002 Feb;43(2):219-24 [11999550.001]
  • [Cites] Br J Haematol. 2002 Sep;118(4):991-8 [12199777.001]
  • [Cites] J Mol Med (Berl). 2003 Jan;81(1):20-31 [12545246.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 Mar;45(3):227-44 [12633837.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):163-4 [12823361.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):663-8 [9012841.001]
  • [Cites] Am J Pathol. 1997 Mar;150(3):815-21 [9060819.001]
  • [Cites] Stem Cells Dev. 2004 Oct;13(5):484-95 [15588506.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1383-95 [15471951.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):1011-27 [15585754.001]
  • [Cites] Oncology. 2000 Feb;58(2):169-74 [10705245.001]
  • (PMID = 17461513.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  • [Other-IDs] NLM/ PMC2628125
  •  go-up   go-down


14. Wang HS, Gao YJ, Li J, Lu FJ, Miao H, Qian XW, Zhu XF: [Clinical characteristics of hepatic veno-occlusive disease in 6 children with hematologic neoplasm treated with 6-thioguanine]. Zhonghua Er Ke Za Zhi; 2010 Sep;48(9):708-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To improve the treatment of drug related childhood hepatic veno-occlusive disease (HVOD), clinical characteristics of 6 children with hematologic neoplasm from 2 hospitals of China Children's Leukemia Group (CCLG) treated with 6-thioguanine (6-TG) complicated with HVOD were analyzed.
  • METHOD: All the drug related HVOD patients were treated with CCLG acute lymphoblastic leukemia (ALL)-2008 protocol.
  • The original disease was acute lymphoblastic leukemia.
  • [MeSH-minor] Child, Preschool. Female. Humans. Leukemia / therapy. Male

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. THIOGUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21092535.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; FTK8U1GZNX / Thioguanine
  •  go-up   go-down


15. Urayama KY, Buffler PA, Gallagher ER, Ayoob JM, Ma X: A meta-analysis of the association between day-care attendance and childhood acute lymphoblastic leukaemia. Int J Epidemiol; 2010 Jun;39(3):718-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A meta-analysis of the association between day-care attendance and childhood acute lymphoblastic leukaemia.
  • BACKGROUND: Childhood acute lymphoblastic leukaemia (ALL) may be the result of a rare response to common infection(s) acquired by personal contact with infected individuals.
  • A meta-analysis was conducted to examine the relationship between day-care attendance and risk of childhood ALL, specifically to address whether early-life exposure to infection is protective against ALL.
  • METHODS: Searches of the PubMed database and bibliographies of publications on childhood leukaemia and infections were conducted.
  • CONCLUSIONS: This analysis provides strong support for an association between exposure to common infections in early childhood and a reduced risk of ALL.

  • MedlinePlus Health Information. consumer health - Child Care.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Paediatr Perinat Epidemiol. 2002 Apr;16(2):154-65 [12060313.001]
  • [Cites] Br J Cancer. 2009 Mar 10;100(5):863 [19259099.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):639-49 [12951583.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):139-45 [14710221.001]
  • [Cites] Am J Epidemiol. 2004 May 15;159(10):915-21 [15128601.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):1-3 [15226760.001]
  • [Cites] Eur J Cancer Prev. 2004 Oct;13(5):397-401 [15452452.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):243-63 [15491284.001]
  • [Cites] Public Health Rep. 2004 Nov-Dec;119(6):521-35 [15504444.001]
  • [Cites] Am J Epidemiol. 1984 May;119(5):788-95 [6720675.001]
  • [Cites] Leuk Res. 1985;9(6):715-33 [3859718.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] Epidemiol Rev. 1987;9:1-30 [3678409.001]
  • [Cites] Leukemia. 1988 Feb;2(2):120-5 [3278171.001]
  • [Cites] Lancet. 1988 Dec 10;2(8624):1323-7 [2904050.001]
  • [Cites] Am J Epidemiol. 1990 Jan;131(1):1-5 [2403464.001]
  • [Cites] Leukemia. 1993 Mar;7(3):349-60 [8445941.001]
  • [Cites] Br J Cancer. 2002 May 6;86(9):1419-24 [11986774.001]
  • [Cites] J Public Health Med. 1993 Mar;15(1):9-15 [8471307.001]
  • [Cites] BMJ. 1993 Sep 25;307(6907):774 [8219951.001]
  • [Cites] Pediatrics. 1994 Dec;94(6 Pt 2):987-90 [7971086.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):1-5 [7819022.001]
  • [Cites] J Epidemiol Community Health. 1994 Dec;48(6):601-2 [7830017.001]
  • [Cites] BMJ. 1995 Mar 25;310(6982):763-8 [7711579.001]
  • [Cites] Epidemiol Rev. 1994;16(2):243-72 [7713179.001]
  • [Cites] Biometrics. 1994 Dec;50(4):1088-101 [7786990.001]
  • [Cites] Epidemiol Rev. 1996;18(1):10-28 [8877328.001]
  • [Cites] Lancet. 1997 Feb 1;349(9048):344-9 [9024390.001]
  • [Cites] Br J Cancer. 1997;76(9):1241-7 [9365177.001]
  • [Cites] Br J Cancer. 1998 Mar;77(5):818-24 [9514064.001]
  • [Cites] Cancer Causes Control. 1998 May;9(3):237-9 [9684703.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):585-90 [10408870.001]
  • [Cites] Blood. 1999 Jul 15;94(2):694-700 [10397736.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1483-9 [10424755.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):4095-9 [10463613.001]
  • [Cites] Int J Epidemiol. 1999 Aug;28(4):631-9 [10480689.001]
  • [Cites] Paediatr Perinat Epidemiol. 2005 Mar;19(2):152-64 [15787890.001]
  • [Cites] BMJ. 2005 Jun 4;330(7503):1294 [15849205.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1928-34 [16103439.001]
  • [Cites] Int J Epidemiol. 2005 Oct;34(5):1100-9 [15951359.001]
  • [Cites] Haematologica. 2006 Feb;91(2):240-3 [16461310.001]
  • [Cites] Eur J Cancer. 2006 Mar;42(4):509-13 [16410049.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):193-203 [16467884.001]
  • [Cites] Br J Cancer. 2006 Jul 3;95(1):102-6 [16755299.001]
  • [Cites] Am J Epidemiol. 2007 Mar 1;165(5):496-504 [17182983.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):146-50 [17366835.001]
  • [Cites] Br J Cancer. 2007 Nov 5;97(9):1315-21 [17923868.001]
  • [Cites] Eur J Cancer. 2007 Nov;43(16):2396-403 [17826085.001]
  • [Cites] Trends Parasitol. 2008 Jan;24(1):35-42 [18055264.001]
  • [Cites] Leukemia. 2008 Jan;22(1):189-93 [17690702.001]
  • [Cites] Am J Epidemiol. 2008 Mar 1;167(5):598-606 [18079130.001]
  • [Cites] Radiat Prot Dosimetry. 2008;132(2):259-66 [18940822.001]
  • [Cites] Hum Mol Genet. 2002 Jul 1;11(14):1585-97 [12075003.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):234-40 [10638995.001]
  • [Cites] Br J Cancer. 2000 Dec;83(11):1559-64 [11076669.001]
  • [Cites] Am J Epidemiol. 2000 Dec 15;152(12):1136-44 [11130619.001]
  • [Cites] Lancet. 2001 Mar 17;357(9259):858 [11265959.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4004-9 [11274424.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2542-6 [11289128.001]
  • [Cites] J Clin Epidemiol. 2001 Oct;54(10):1046-55 [11576817.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1064-9 [11953850.001]
  • [CommentIn] Int J Epidemiol. 2011 Feb;40(1):258-9 [20430829.001]
  • (PMID = 20110276.001).
  • [ISSN] 1464-3685
  • [Journal-full-title] International journal of epidemiology
  • [ISO-abbreviation] Int J Epidemiol
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / PS42 ES04705; United States / NIEHS NIH HHS / ES / R01 ES09137
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2878455
  •  go-up   go-down


16. Vyas P, Roberts I: Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis. Early Hum Dev; 2006 Dec;82(12):767-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.
  • Newborns and children with Down Syndrome are predisposed to a range of blood disorders, which include acute lymphoblastic leukaemia and acute megakaryocytic leukaemia (AMKL).
  • Like other childhood leukaemias DS AMKL is initiated in utero and can present in the neonatal period as a clinically overt preleukaemic condition, transient myeloproliferative disorder (TMD).
  • Thus, DS TMD and AMKL provide a unique model of childhood leukaemia where the preleukaemic and leukaemic phases are ascertainable and separable allowing distinct steps in leukaemogenesis to be studied individually.
  • These findings also have implications for the clinical management of DS TMD and AMKL specifically and also of childhood leukaemia more generally.
  • [MeSH-major] Down Syndrome / complications. Leukemia, Megakaryoblastic, Acute / physiopathology. Megakaryocytes / physiology. Thrombopoiesis / physiology

  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17064858.001).
  • [ISSN] 0378-3782
  • [Journal-full-title] Early human development
  • [ISO-abbreviation] Early Hum. Dev.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human
  • [Number-of-references] 23
  •  go-up   go-down


17. Wayne AS, Reaman GH, Helman LJ: Progress in the curative treatment of childhood hematologic malignancies. J Natl Cancer Inst; 2008 Sep 17;100(18):1271-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progress in the curative treatment of childhood hematologic malignancies.
  • [MeSH-minor] Child. Clinical Trials as Topic. Disease-Free Survival. Health Status. Hodgkin Disease / mortality. Hodgkin Disease / therapy. Humans. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / therapy. Mortality / trends. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Quality of Life. Survival Rate. Treatment Outcome. United States / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Natl Cancer Inst. 2008 Sep 17;100(18):1301-9 [18780868.001]
  • (PMID = 18780861.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


18. Holleman A, den Boer ML, Kazemier KM, Beverloo HB, von Bergh AR, Janka-Schaub GE, Pieters R: Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia. Blood; 2005 Sep 1;106(5):1817-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia.
  • Drug resistance in childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) is associated with impaired ability to induce apoptosis.
  • To elucidate causes of apoptotic defects, we studied the protein expression of Apaf-1, procaspases-2, -3, -6, -7, -8, -10, and poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) in cells from children with acute lymphoblastic leukemia (ALL; n = 43) and acute myeloid leukemia (AML; n = 10).
  • In conclusion, low baseline expression of PARP and procaspase-2 is related to cellular drug resistance in childhood acute lymphoblastic leukemia.
  • [MeSH-major] Caspases / metabolism. Drug Resistance, Neoplasm / physiology. Poly(ADP-ribose) Polymerases / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism


19. Jeha S, Behm F, Pei D, Sandlund JT, Ribeiro RC, Razzouk BI, Rubnitz JE, Hijiya N, Howard SC, Cheng C, Pui CH: Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood; 2006 Nov 15;108(10):3302-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia.
  • CD20 expression is associated with inferior survival in adults with acute lymphoblastic leukemia (ALL).
  • These data suggest that CD20 expression is not associated with inferior outcome in pediatric patients treated with contemporary regimens.


20. Davis CF, Dorak MT: An extensive analysis of the hereditary hemochromatosis gene HFE and neighboring histone genes: associations with childhood leukemia. Ann Hematol; 2010 Apr;89(4):375-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An extensive analysis of the hereditary hemochromatosis gene HFE and neighboring histone genes: associations with childhood leukemia.
  • The most common mutation of the HFE gene C282Y has shown a risk association with childhood acute lymphoblastic leukemia (ALL) in Welsh and Scottish case-control studies.
  • Here, we present a thorough analysis of the HFE gene in a panel of HLA homozygous reference cell lines and in the original population sample from South Wales (117 childhood ALL cases and 414 newborn controls).
  • In the HapMap project data, rs807212 was in strong linkage disequilibrium with 25 other SNPs spanning 151 kb around HFE.
  • [MeSH-major] Genetic Predisposition to Disease. Histocompatibility Antigens Class I / genetics. Histones / genetics. Membrane Proteins / genetics. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Hemochromatosis.
  • Genetic Alliance. consumer health - Hereditary hemochromatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19806355.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / HFE protein, human; 0 / Histocompatibility Antigens Class I; 0 / Histones; 0 / Membrane Proteins
  •  go-up   go-down


21. Vijayakrishnan J, Houlston RS: Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Haematologica; 2010 Aug;95(8):1405-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: a systematic review and meta-analysis.
  • To evaluate the contribution of candidate gene association studies to the understanding of genetic susceptibility to childhood acute lymphoblastic leukemia we conducted a systematic review and meta-analysis of published studies (January 1996-July 2009).
  • We identified 47 studies of polymorphic variation in 16 genes and acute lymphoblastic leukemia risk.
  • [MeSH-major] Genetic Predisposition to Disease / genetics. Genome-Wide Association Study / methods. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


22. Zhang ZX, Cao LZ, Huang Q, Yang MH, Wang Z, Yu Y: [Detection of human cyclin C gene expression in childhood acute lymphocytic leukemia using real-time fluorescence quantitative PCR]. Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb;10(1):14-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of human cyclin C gene expression in childhood acute lymphocytic leukemia using real-time fluorescence quantitative PCR].
  • OBJECTIVE: To explore the relationship between human cyclin C (CCNC) gene and childhood acute lymphocytic leukemia (ALL).
  • METHODS: The total RNA isolated from myeloid tissues of normal children and of children with newly diagnosed ALL and from ALL cell line 6T-CEM was reversely transcribed into cDNA.
  • RESULTS: CCNC was expressed in myeloid tissues of normal children and of children with newly diagnosed ALL as well as 6T-CEM.
  • CONCLUSIONS: CCNC gene shows lower expression in children with newly diagnosed ALL, suggesting that it may be a tumor suppressing gene in childhood ALL.
  • [MeSH-major] Cyclins / genetics. Polymerase Chain Reaction / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289462.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CCNC protein, human; 0 / Cyclin C; 0 / Cyclins
  •  go-up   go-down


23. Krappmann P, Paulides M, Stöhr W, Ittner E, Plattig B, Nickel P, Lackner H, Schrappe M, Janka G, Beck JD, Langer T: Almost normal cognitive function in patients during therapy for childhood acute lymphoblastic leukemia without cranial irradiation according to ALL-BFM 95 and COALL 06-97 protocols: results of an Austrian-German multicenter longitudinal study and implications for follow-up. Pediatr Hematol Oncol; 2007 Mar;24(2):101-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Almost normal cognitive function in patients during therapy for childhood acute lymphoblastic leukemia without cranial irradiation according to ALL-BFM 95 and COALL 06-97 protocols: results of an Austrian-German multicenter longitudinal study and implications for follow-up.
  • In a multicenter study the authors prospectively investigated neurocognitive function in childhood ALL patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cognition Disorders / chemically induced. Cranial Irradiation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454775.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; ZS7284E0ZP / Daunorubicin; ALL-BFM-95 protocol
  •  go-up   go-down


24. Uyttebroeck A, Suciu S, Laureys G, Robert A, Pacquement H, Ferster A, Marguerite G, Mazingue F, Renard M, Lutz P, Rialland X, Mechinaud F, Cavé H, Baila L, Bertrand Y, Children's Leukaemia Group (CLG) of the European Organisation for Research and Treatment of Cancer (EORTC): Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer; 2008 Apr;44(6):840-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial.
  • From June 1989 through to November 1998, 121 children with newly diagnosed T-cell lymphoblastic lymphoma (T-LBL) were included in the EORTC 58881 trial conducted by the Children's Leukaemia Group.
  • An intensive acute lymphoblastic leukaemia type chemotherapy regimen without irradiation leads to a high cure and survival rate in childhood T-LBL without an increased CNS recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342502.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10-CA11488-18; United States / NCI NIH HHS / CA / 5U10-CA11488-19; United States / NCI NIH HHS / CA / 5U10-CA11488-20; United States / NCI NIH HHS / CA / 5U10-CA11488-21; United States / NCI NIH HHS / CA / 5U10-CA11488-22; United States / NCI NIH HHS / CA / 5U10-CA11488-23; United States / NCI NIH HHS / CA / 5U10-CA11488-24; United States / NCI NIH HHS / CA / 5U10-CA11488-25; United States / NCI NIH HHS / CA / 5U10-CA11488-26; United States / NCI NIH HHS / CA / 5U10-CA11488-27; United States / NCI NIH HHS / CA / 5U10-CA11488-28; United States / NCI NIH HHS / CA / 5U10-CA11488-29; United States / NCI NIH HHS / CA / 5U10-CA11488-30; United States / NCI NIH HHS / CA / 5U10-CA11488-31; United States / NCI NIH HHS / CA / 5U10-CA11488-32; United States / NCI NIH HHS / CA / 5U10-CA11488-33; United States / NCI NIH HHS / CA / 5U10-CA11488-34; United States / NCI NIH HHS / CA / 5U10-CA11488-35; United States / NCI NIH HHS / CA / 5U10-CA11488-36
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Philippet P; Otten J; Plouvier E; Béhar C; Boutard P; Millot F; Waterkeyn C; Velde IV; Solbu G
  •  go-up   go-down


25. Wright MJ, Galea V, Barr RD: Proficiency of balance in children and youth who have had acute lymphoblastic leukemia. Phys Ther; 2005 Aug;85(8):782-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proficiency of balance in children and youth who have had acute lymphoblastic leukemia.
  • BACKGROUND AND PURPOSE: As the survival rate for acute lymphoblastic leukemia (ALL) in childhood increases, long-term sequelae are a growing concern.
  • [MeSH-major] Motor Skills Disorders / physiopathology. Postural Balance. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Psychomotor Disorders / physiopathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16048425.001).
  • [ISSN] 0031-9023
  • [Journal-full-title] Physical therapy
  • [ISO-abbreviation] Phys Ther
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA68484
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


26. Ong V, Liem NL, Schmid MA, Verrills NM, Papa RA, Marshall GM, Mackenzie KL, Kavallaris M, Lock RB: A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts. J Pharmacol Exp Ther; 2008 Feb;324(2):434-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts.
  • The microtubule-depolymerizing drug, vincristine, is effective in the treatment of acute lymphoblastic leukemia (ALL).
  • The aim of the current study was to define clinically relevant mechanisms of vincristine resistance in a panel of childhood ALL xenografts established in immune-deficient (nonobese diabetic/severe combined immunodeficient) mice.
  • These results indicate that the balance between polymerized and nonpolymerized tubulin may be an important determinant of response to Vinca alkaloid-based chemotherapy regimens in childhood ALL.
  • [MeSH-major] Drug Resistance, Neoplasm / physiology. Microtubules / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Vincristine / therapeutic use. Xenograft Model Antitumor Assays / methods

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986648.001).
  • [ISSN] 1521-0103
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01-CM-42216
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Polymers; 5J49Q6B70F / Vincristine
  •  go-up   go-down


27. Meleshko AN, Lipay NV, Stasevich IV, Potapnev MP: Rearrangements of IgH, TCRD and TCRG genes as clonality marker of childhood acute lymphoblastic leukemia. Exp Oncol; 2005 Dec;27(4):319-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rearrangements of IgH, TCRD and TCRG genes as clonality marker of childhood acute lymphoblastic leukemia.
  • AIM: Immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements are excellent patient-specific targets for clonality studies and monitoring of acute lymphoblastic leukemia (ALL).
  • Seven pair cases of patients with de novo leukemia and relapses were analyzed and revealed subclonal deviation in rearrangements of IgH or TCR genes during disease evolution.
  • [MeSH-major] Gene Rearrangement, B-Lymphocyte, Heavy Chain. Gene Rearrangement, delta-Chain T-Cell Antigen Receptor. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


28. Mitchell C, Payne J, Wade R, Vora A, Kinsey S, Richards S, Eden T: The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99. Br J Haematol; 2009 Aug;146(4):424-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99.
  • The 1997 acute lymphoblastic leukaemia (ALL) trial (ALL97) was a randomised comparison of prednisolone versus dexamethasone and of 6-mercaptopurine versus 6-thioguanine.
  • During the first 2 years of the trial, review of survival data showed the preceding trial, UKALL XI, was no better than its predecessor and that survival for childhood ALL in the UK had not improved in the fashion witnessed by other cooperative treatment groups.
  • There were no significant differences for non-CNS relapse, induction deaths or deaths in remission between the two phases of the trial.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Marrow Cells / immunology. Immunosuppressive Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19549269.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300130; United Kingdom / Medical Research Council / / MC/ U137686856; United Kingdom / Medical Research Council / / 98223452
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  •  go-up   go-down


29. Schrappe M: Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia. Radiat Prot Dosimetry; 2008;132(2):130-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia.
  • Systematic enrollment of children and adolescents with acute lymphoblastic leukaemia (ALL) into clinical trials has allowed the establishment of prognostic parameters derived from initial diagnostic findings.
  • More important, these trials have significantly contributed to the reduction of disease recurrence as much as to the reduction of acute and late side effects.
  • [MeSH-major] Clinical Trials as Topic. Disease Outbreaks / statistics & numerical data. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Risk Assessment / methods

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19017727.001).
  • [ISSN] 0144-8420
  • [Journal-full-title] Radiation protection dosimetry
  • [ISO-abbreviation] Radiat Prot Dosimetry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


30. Jiang H, Gu LJ, Xue HL, Tang JY, Chen J, Pan C, Chen J: [Asparagine synthetase activity in pediatric acute lymphoblastic leukemia]. Zhongguo Dang Dai Er Ke Za Zhi; 2006 Aug;8(4):272-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Asparagine synthetase activity in pediatric acute lymphoblastic leukemia].
  • OBJECTIVE: To study the cellular activity of asparagine synthetase in different types of childhood acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Aspartate-Ammonia Ligase / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923354.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / TEL-AML1 fusion protein; EC 3.5.1.1 / Asparaginase; EC 6.3.1.1 / Aspartate-Ammonia Ligase
  •  go-up   go-down


31. Catusse J, Wollner S, Leick M, Schröttner P, Schraufstätter I, Burger M: Attenuation of CXCR4 responses by CCL18 in acute lymphocytic leukemia B cells. J Cell Physiol; 2010 Nov;225(3):792-800
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Attenuation of CXCR4 responses by CCL18 in acute lymphocytic leukemia B cells.
  • Elevated levels of CCL18 have been described in various diseases including childhood acute lymphocytic leukemia (ALL) but its functions remain poorly characterized.
  • [MeSH-major] Chemokines, CC / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cells, B-Lymphoid / immunology. Receptors, CXCR4 / metabolism. Signal Transduction

  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley-Liss, Inc.
  • (PMID = 20568229.001).
  • [ISSN] 1097-4652
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCL18 protein, human; 0 / CXCL12 protein, human; 0 / CXCR4 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CC; 0 / Estrogen Antagonists; 0 / GPER protein, human; 0 / Ligands; 0 / Receptors, CXCR4; 0 / Receptors, Estrogen; 0 / Receptors, G-Protein-Coupled; 0 / Recombinant Proteins; 4TI98Z838E / Estradiol
  •  go-up   go-down


32. Simon C, Eder M, Kodish E, Siminoff L: Altruistic discourse in the informed consent process for childhood cancer clinical trials. Am J Bioeth; 2006 Sep-Oct;6(5):40-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altruistic discourse in the informed consent process for childhood cancer clinical trials.
  • We analyzed 140 audiotaped pediatric informed consent sessions, of which 95 (68%) included at least one discussion of how participation in a cancer clinical trial might benefit:.
  • 2) other children with cancer specifically; and 3) "the future" and other vaguely defined recipients.
  • While further research on this topic is warranted, bioethical debate should strive to reflect the diversity of altruistic discourse in clinical research encounters and to place this discourse in the context of other, including nonaltruistic, considerations.
  • [MeSH-minor] Acute Disease. Adult. Child. Female. Humans. Knowledge. Leukemia, Myeloid / therapy. Male. Middle Aged. Physician's Role. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Research Personnel. Tape Recording. United States

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Bioeth. 2006 Sep-Oct;6(5):52 [16997829.001]
  • [CommentIn] Am J Bioeth. 2006 Sep-Oct;6(5):51-2 [16997828.001]
  • [CommentIn] Am J Bioeth. 2006 Sep-Oct;6(5):49-50 [16997827.001]
  • [CommentIn] Am J Bioeth. 2006 Sep-Oct;6(5):53-4 [16997830.001]
  • [CommentIn] Am J Bioeth. 2006 Sep-Oct;6(5):55-6 [16997831.001]
  • [CommentIn] Am J Bioeth. 2006 Sep-Oct;6(5):48 [16997826.001]
  • (PMID = 16997825.001).
  • [ISSN] 1536-0075
  • [Journal-full-title] The American journal of bioethics : AJOB
  • [ISO-abbreviation] Am J Bioeth
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA83267
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


33. Meleshko AN, Movchan LV, Belevtsev MV, Savitskaja TV: Relative expression of different Ikaros isoforms in childhood acute leukemia. Blood Cells Mol Dis; 2008 Nov-Dec;41(3):278-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative expression of different Ikaros isoforms in childhood acute leukemia.
  • We estimate the relative level of Ikaros mRNA transcripts in 80 childhood ALL cases in comparison with AML and healthy donor groups.
  • We detected eight major isoforms and several minor mutant isoforms in most patients with acute lymphoblastic and myeloid leukemia and in healthy donors, but the relative level of expression varied.
  • We found a negative association between the Ikaros ratio and myeloid coexpression in B-cell ALL, the most prominent was for CD15.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Ikaros Transcription Factor / genetics. Leukemia / genetics

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18675565.001).
  • [ISSN] 1096-0961
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mutant Proteins; 0 / Protein Isoforms; 148971-36-2 / Ikaros Transcription Factor
  •  go-up   go-down


34. O'Leary M, Krailo M, Anderson JR, Reaman GH, Children's Oncology Group: Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group. Semin Oncol; 2008 Oct;35(5):484-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group.
  • The Children's Oncology Group (COG) recently celebrated the milestone of 50 years of pediatric clinical trials and collaborative research in oncology.
  • Our group had its origins in the four legacy pediatric clinical trials groups: the Children's Cancer Group (CCG), the Pediatric Oncology Group (POG), the National Wilms' Tumor Study Group (NWTS), and the Intergroup Rhabdomyosarcoma Study Group (IRSG), which merged in 2000 to form the COG.
  • Over the last 50 years, the survival rates for childhood cancer have risen from 10% to almost 80%.
  • Outcome in acute lymphoblastic leukemia (ALL) has gone from a 6-month median survival to an 80% overall cure rate.
  • Experience has clearly proven that everything we know about the diagnosis and management of childhood cancer is a result of research and the dramatic historical decrease in mortality from childhood cancer is directly related to cooperative group clinical research.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Children's Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2127-36 [10561268.001]
  • [Cites] Cancer. 1993 Apr 1;71(7):2423 [8453565.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):718-28 [11597814.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1986-94 [11877270.001]
  • [Cites] N Engl J Med. 2003 Feb 20;348(8):694-701 [12594313.001]
  • [Cites] Blood. 2003 May 15;101(10):3809-17 [12531809.001]
  • [Cites] Cancer. 1968 Mar;21(3):346-51 [5237296.001]
  • [Cites] N Engl J Med. 1968 Aug 8;279(6):290-4 [4298260.001]
  • [Cites] Cancer. 1969 Jun;23(6):1296-304 [5253730.001]
  • [Cites] Cancer. 1976 Aug;38(2):633-46 [184912.001]
  • [Cites] Cancer. 1978 May;41(5):1937-48 [206343.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1979 Spring;1(1):9-13 [295576.001]
  • [Cites] Cancer. 1980 Aug 1;46(3):516-21 [6772293.001]
  • [Cites] Cancer. 1981 May 1;47(9):2302-11 [6164480.001]
  • [Cites] Natl Cancer Inst Monogr. 1981 Apr;(56):263-71 [7029294.001]
  • [Cites] Cancer Res. 1982 Feb;42(2):674-80 [7034927.001]
  • [Cites] J Clin Oncol. 1983 May;1(5):308-16 [6366137.001]
  • [Cites] N Engl J Med. 1986 Jun 19;314(25):1600-6 [3520317.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):209-20 [3275486.001]
  • [Cites] J Clin Oncol. 1988 Dec;6(12):1874-81 [3199170.001]
  • [Cites] J Clin Oncol. 1989 Feb;7(2):236-44 [2915240.001]
  • [Cites] Cancer. 1989 Jul 15;64(2):349-60 [2544249.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1539-44 [2778483.001]
  • [Cites] J Clin Oncol. 1990 Mar;8(3):443-52 [2407808.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):572-82 [2319316.001]
  • [Cites] Med Pediatr Oncol. 1990;18(4):273-9 [2355886.001]
  • [Cites] Blood. 1990 Aug 1;76(3):489-94 [2378982.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):18-24 [8558195.001]
  • [Cites] Cancer. 1996 Sep 15;78(6):1330-2 [8826958.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):237-45 [9440748.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3744-51 [9850017.001]
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1165-73 [10519894.001]
  • [Cites] J Am Med Assoc. 1950 Dec 16;144(16):1349-53 [14778746.001]
  • [Cites] Blood. 1953 Nov;8(11):965-99 [13105700.001]
  • [Cites] Cancer Chemother Rep. 1965 Apr;45:45-51 [14328048.001]
  • [Cites] Blood. 1960 Mar;15:350-9 [14401649.001]
  • [Cites] J Clin Oncol. 2005 Oct 10;23(29):7312-21 [16129848.001]
  • [Cites] Blood. 2006 Jul 15;108(2):441-51 [16556894.001]
  • [Cites] Blood. 2006 Jul 15;108(2):711-7 [16822902.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2736-43 [17138821.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] N Engl J Med. 1948 Jun 3;238(23):787-93 [18860765.001]
  • [Cites] Cancer. 1948 Sep;1(3):399-412 [18887906.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1514-24 [2099751.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1106-13 [2205352.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1183-9 [2205354.001]
  • [Cites] J Clin Oncol. 1990 Oct;8(10):1664-74 [2213103.001]
  • [Cites] Cancer. 1991 Jan 15;67(2):331-6 [1845940.001]
  • [Cites] Pediatr Hematol Oncol. 1990;7(4):329-38 [2268533.001]
  • [Cites] N Engl J Med. 1991 Nov 7;325(19):1330-6 [1922234.001]
  • [Cites] J Clin Oncol. 1991 Dec;9(12):2167-76 [1720452.001]
  • [Cites] Blood. 1992 Jun 15;79(12):3316-24 [1596572.001]
  • [Cites] Blood. 1992 Nov 1;80(9):2210-4 [1384797.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):96-9 [8380296.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1904-22 [8448756.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2665-75 [10894865.001]
  • (PMID = 18929147.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543-06; None / None / / U10 CA098413-04; United States / NCI NIH HHS / CA / U10 CA098413-04; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / CA 98543; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA98413; None / None / / U10 CA098543-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 66
  • [Other-IDs] NLM/ NIHMS73614; NLM/ PMC2702720
  •  go-up   go-down


35. Kamdem LK, Hamilton L, Cheng C, Liu W, Yang W, Johnson JA, Pui CH, Relling MV: Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia. Pharmacogenet Genomics; 2008 Jun;18(6):507-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia.
  • OBJECTIVE: Glucocorticoids are used universally in the remission induction therapy for acute lymphoblastic leukemia (ALL).
  • Hypertension was defined according to the guidelines of the American Academy of Pediatrics; patients were evaluated during the 28-day period of prednisone at 40 mg/m2/day during remission induction of childhood ALL.
  • [MeSH-major] Glucocorticoids / adverse effects. Hypertension / chemically induced. Hypertension / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827853880 for PMID:18496130 [PharmGKB] .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18496130.001).
  • [ISSN] 1744-6872
  • [Journal-full-title] Pharmacogenetics and genomics
  • [ISO-abbreviation] Pharmacogenet. Genomics
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA070089; United States / NCI NIH HHS / CA / CA 36401; United States / NCI NIH HHS / CA / CA 51001; United States / NCI NIH HHS / CA / T32-CA070089; United States / NIGMS NIH HHS / GM / U01GM61374; United States / NCI NIH HHS / CA / CA21765; United States / NIGMS NIH HHS / GM / U01 GM61393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / CYP3A protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A
  •  go-up   go-down


36. Otsubo K, Kanegane H, Eguchi M, Eguchi-Ishimae M, Tamura K, Nomura K, Abe A, Ishii E, Miyawaki T: ETV6-ARNT fusion in a patient with childhood T lymphoblastic leukemia. Cancer Genet Cytogenet; 2010 Oct 1;202(1):22-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ETV6-ARNT fusion in a patient with childhood T lymphoblastic leukemia.
  • Leukemia with t(1;12)(q21;p13) was previously described in a 5-year-old boy with acute myeloblastic leukemia (AML-M2) who exhibited a novel ETV6-aryl hydrocarbon receptor nuclear translocator (ARNT) fusion protein.
  • We herein report the case of a 2-year-old boy with T-cell lymphoblastic leukemia (T-ALL) harboring t(1;12)(q21;p13).
  • To our knowledge, the current report is novel in its report of the ETV6-ARNT fusion in childhood T-ALL.
  • [MeSH-major] ARNTL Transcription Factors / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20804916.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ARNTL Transcription Factors; 0 / DNA Primers; 0 / ETS translocation variant 6 protein; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins
  •  go-up   go-down


37. Earle EA, Clarke SA, Eiser C, Sheppard L: 'Building a new normality': mothers' experiences of caring for a child with acute lymphoblastic leukaemia. Child Care Health Dev; 2007 Mar;33(2):155-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Building a new normality': mothers' experiences of caring for a child with acute lymphoblastic leukaemia.
  • BACKGROUND: Treatment of childhood cancer occurs over a 2- to 3-year period, with initial intense phases of chemotherapy followed by less severe treatment periods.
  • METHODS: This study was longitudinal and involved a cross section of 32 mothers of children recently diagnosed with acute lymphoblastic leukaemia (ALL) currently participating in the Medical Research Council ALL-97 randomized control trial.
  • [MeSH-major] Family Health. Life Style. Mothers / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17291319.001).
  • [ISSN] 0305-1862
  • [Journal-full-title] Child: care, health and development
  • [ISO-abbreviation] Child Care Health Dev
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


38. Hu R, Yan Y, Li Q, Lin Y, Jin W, Li H, Lu Y, Pang T: Increased drug efflux along with midkine gene high expression in childhood B-lineage acute lymphoblastic leukemia cells. Int J Hematol; 2010 Jul;92(1):105-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased drug efflux along with midkine gene high expression in childhood B-lineage acute lymphoblastic leukemia cells.
  • Multidrug resistance (MDR) induced by drug efflux has been identified as the major clinical obstacle in the treatment of childhood acute lymphoblastic leukemia (ALL).
  • In the Rhodamine 123 (Rh123) efflux test, mean fluorescence intensity (MFI) in the leukemia cells was obviously lower than that in normal pre-B cells (p < 0.01).
  • We concluded that there was powerful drug efflux ability in lymphoblastic leukemia cells with high MK gene expression.
  • [MeSH-major] Drug Resistance, Multiple / genetics. Gene Expression Regulation, Leukemic. Nerve Growth Factors / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2006 Feb 13;580(4):998-1009 [16405967.001]
  • [Cites] Neurosci Res. 2003 Feb;45(2):219-24 [12573468.001]
  • [Cites] Oral Oncol. 2004 Mar;40(3):274-80 [14747058.001]
  • [Cites] J Biochem. 2002 Sep;132(3):359-71 [12204104.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2430-6 [15160348.001]
  • [Cites] Cancer Sci. 2003 Jan;94(1):15-21 [12708468.001]
  • [Cites] Leuk Res. 2007 Aug;31(8):1045-51 [17267033.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Nov;50(5):343-52 [12439591.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4294-301 [15205344.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):272-84 [14734480.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):35990-8 [12122009.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):701-6 [10952771.001]
  • [Cites] Oncogene. 2005 Jul 21;24(31):4965-74 [15897897.001]
  • [Cites] Nagoya J Med Sci. 2005 Jun;67(3-4):71-82 [17375473.001]
  • [Cites] Exp Hematol. 2008 Apr;36(4):433-42 [18249061.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8486-91 [11731432.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13266-71 [16141323.001]
  • [Cites] J Biochem. 2000 Feb;127(2):269-77 [10731694.001]
  • (PMID = 20544404.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / MDK protein, human; 0 / Nerve Growth Factors
  •  go-up   go-down


39. Yang MH, Cao LZ, Yu Y, Zhang ZX, Wang Y, Kang R, Chen Y, Tan ZH, Wu XS: [Allelic loss of 6q16.3 microsatellite DNA in childhood acute lymphoblastic leukemia and bioinformatics analysis]. Zhonghua Xue Ye Xue Za Zhi; 2006 May;27(5):289-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Allelic loss of 6q16.3 microsatellite DNA in childhood acute lymphoblastic leukemia and bioinformatics analysis].
  • OBJECTIVE: To locate the cluster region of loss of heterozygosity (LOH) in children with acute lymphoblastic leukemia (ALL), and explore the new tumor suppressor gene.
  • [MeSH-major] Chromosomes, Human, Pair 6 / genetics. Loss of Heterozygosity. Microsatellite Repeats / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875573.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


40. Dłuzniewska A, Balwierz W, Balcerska A, Chybicka A, Kamieńska E, Karolczyk G, Karpińska-Derda I, Krawczuk-Rybak M, Kowalczyk JR, Lewandowska D, Maciejka-Kapuścińska L, Kołtano S, Malinowska I, Matysiak M, Mikołajczyk M, Mizia-Malarz A, Muszyńska-Rosłan K, Niedźwiedzki M, Pohorecka J, Sikorska-Fic B, Sobol G, Sońta-Jakimczyk D, Tomaszewska R, Urasiński T, Wachowiak J, Wieczorek M, Wójcik B, Wysocki M: [Treatment failure in children with acute myelocytic leukemia: over 25-year experience of Polish Pediatric Leukemia/Lymphoma Study Group with four consecutive unified treatment protocols for childhood acute myelocytic leukemia]. Przegl Lek; 2010;67(6):366-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment failure in children with acute myelocytic leukemia: over 25-year experience of Polish Pediatric Leukemia/Lymphoma Study Group with four consecutive unified treatment protocols for childhood acute myelocytic leukemia].
  • Four consecutive intensive unified regimens (BFM-AML-83, PGP-AML 94, PGP-AML 98 AML-BFM 2004 Interim) for acute myelocytic leukemia (AML) have been conducted by the Polish Pediatric Leukemia/Lymphoma Study Group (PPLLSG) since 1983.
  • Number of non responders increased between first and second period from 6% to 18%, later decreased to 8.2% at present.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21344763.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


41. Settin A, Al Haggar M, Al Dosoky T, Al Baz R, Abdelrazik N, Fouda M, Aref S, Al-Tonbary Y: Prognostic cytogenetic markers in childhood acute lymphoblastic leukemia: cases from Mansoura, Egypt. Hematology; 2006 Oct;11(5):341-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic cytogenetic markers in childhood acute lymphoblastic leukemia: cases from Mansoura, Egypt.
  • OBJECTIVE: To evaluate children with acute lymphoblastic leukemia (ALL) showing resistance to immediate induction chemotherapy in relation to conventional and advanced cytogenetic analysis.
  • Initially low Hb < 8 gm/dl, high WBCs and platelet counts > 50,000/mm(3) also showed better but non-significant remission rates.
  • Most of our cases were L(2) with better remission compared to other immunophenotypes.
  • CONCLUSIONS: Cytogenetic and molecular characterizations of childhood ALL may add prognostic criteria for optimal therapy allocation.
  • [MeSH-major] Cytogenetic Analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis


42. Davies JH, Evans BA, Jenney ME, Gregory JW: Skeletal morbidity in childhood acute lymphoblastic leukaemia. Clin Endocrinol (Oxf); 2005 Jul;63(1):1-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skeletal morbidity in childhood acute lymphoblastic leukaemia.
  • [MeSH-major] Bone Diseases, Metabolic / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15963054.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Glucocorticoids; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 87
  •  go-up   go-down


43. McKinney PA, Raji OY, van Tongeren M, Feltbower RG: The UK Childhood Cancer Study: maternal occupational exposures and childhood leukaemia and lymphoma. Radiat Prot Dosimetry; 2008;132(2):232-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The UK Childhood Cancer Study: maternal occupational exposures and childhood leukaemia and lymphoma.
  • Risks of childhood leukaemia and lymphoma were investigated for specific work-related exposures of mothers in the UK Childhood Cancer Study.
  • For self-reported exposure, significant risks of acute lymphoblastic leukaemia (ALL) were observed for solvents and petrol in all time windows.
  • [MeSH-major] Carcinogens / analysis. Environmental Monitoring / statistics & numerical data. Leukemia / epidemiology. Lymphoma / epidemiology. Maternal Exposure / statistics & numerical data. Occupational Exposure / analysis. Occupational Exposure / statistics & numerical data. Prenatal Exposure Delayed Effects / epidemiology


44. Liu XP, Zhu XF, Wang JX, Mi YC, Zou Y, Chen YM, Li CW, Dai Y, Qin S, Xiao JG, Xu FY, Gong JY, Wang SP, Yu CL, Fan J: [A comparative cytogenetic analysis in large scale between adult and childhood patients with acute lymphoblastic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec;17(6):1399-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A comparative cytogenetic analysis in large scale between adult and childhood patients with acute lymphoblastic leukemia].
  • This study was purposed to comparatively analyze the cytogenetic characteristics between 566 cases of adult acute lymphoblastic leukemia (aALL) and 586 cases of childhood acute lymphoblastic leukemia (cALL).

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20030914.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


45. Linabery AM, Ross JA: Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999. Cancer; 2008 Nov 1;113(9):2575-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999.
  • In the current study, updated childhood and adolescent cancer survival statistics are presented, overall and among demographic subgroups, including Hispanics, for whom to the authors' knowledge national rates have not been previously reported.
  • Rates in Hispanic children and adolescents were compared with those in non-Hispanic whites and blacks (SEER 13, 1995-1999).
  • RESULTS: Five-year survival rates increased significantly overall (1975-1979: 63% vs 1995-1999: 79%; P< .0001) and for nearly all histologic types examined; increases were greatest for ependymoma (+37%; P< .0001) and non-Hodgkin lymphoma (+34%; P< .0001).
  • Hispanic children and adolescents had somewhat poorer 5-year rates than non-Hispanic whites overall (74% vs 81%; P< .0001) and for Ewing sarcoma, leukemia, central nervous system tumors, and melanoma.
  • The largest improvements were noted for acute lymphoblastic leukemia (+19%; P< .0001) and non-Hodgkin lymphoma (+19%; P< .0001).

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2004 Dec;15(10):1027-34 [15801487.001]
  • [Cites] Lancet. 2004 Dec 11-17;364(9451):2097-105 [15589307.001]
  • [Cites] Cancer J. 2005 Jul-Aug;11(4):340-54 [16197724.001]
  • [Cites] BMJ. 2005 Dec 3;331(7528):1295 [16299015.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1162-8 [16429450.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):578-81 [16537719.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1711-42 [16958083.001]
  • [Cites] Cancer Causes Control. 2007 Mar;18(2):177-87 [17219013.001]
  • [Cites] CA Cancer J Clin. 2007 Jul-Aug;57(4):242-55 [17626120.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7 Suppl):1070-3 [17943956.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7 Suppl):1074-82 [17943961.001]
  • [Cites] Nat Rev Cancer. 2008 Apr;8(4):288-98 [18354417.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1339-45 [12599243.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):203-16 [12612655.001]
  • [Cites] Curr Opin Pediatr. 2004 Feb;16(1):9-14 [14758108.001]
  • [Cites] Cancer Treat Rev. 2004 May;30(3):269-80 [15059650.001]
  • [Cites] J Pediatr Oncol Nurs. 2004 May-Jun;21(3):123-7 [15296038.001]
  • [Cites] Biometrics. 1983 Dec;39(4):941-8 [6671129.001]
  • [Cites] JAMA. 1995 Feb 22;273(8):633-7 [7844873.001]
  • [Cites] Epidemiol Rev. 1994;16(2):243-72 [7713179.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2343-50 [8635041.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):201-7 [8630931.001]
  • [Cites] Int J Cancer. 1996 Dec 11;68(6):759-65 [8980180.001]
  • [Cites] J Adolesc Health. 1997 Dec;21(6):366-73 [9401854.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1269-77 [9731733.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 16;91(12):1051-8 [10379968.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):39-49 [16173961.001]
  • (PMID = 18837040.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA099936-04; United States / NCI NIH HHS / CA / T32 CA099936; United States / NCI NIH HHS / CA / T32 CA099936-04
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS70883; NLM/ PMC2765225
  •  go-up   go-down


46. Jurek AM, Maldonado G, Spector LG, Ross JA: Periconceptional maternal vitamin supplementation and childhood leukaemia: an uncertainty analysis. J Epidemiol Community Health; 2009 Feb;63(2):168-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periconceptional maternal vitamin supplementation and childhood leukaemia: an uncertainty analysis.
  • BACKGROUND: Recent studies in childhood cancer suggest that maternal vitamin supplementation may reduce the risk of leukaemia, neuroblastoma and certain types of childhood brain tumours.
  • For example, a previous study found a significantly reduced risk of acute lymphoblastic leukaemia (ALL) but not acute myeloid leukaemia (AML) in children with Down syndrome whose mothers reported any vitamin supplement use prior to knowledge of pregnancy (ALL OR adjusted for confounders 0.51, 95% confidence limits (CL): 0.30, 0.89; AML OR adjusted for confounders 0.92, 95% CL 0.48, 1.76).

  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • MedlinePlus Health Information. consumer health - Preconception Care.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Epidemiol Community Health. 2009 Feb;63(2):91 [19141660.001]
  • (PMID = 18977808.001).
  • [ISSN] 1470-2738
  • [Journal-full-title] Journal of epidemiology and community health
  • [ISO-abbreviation] J Epidemiol Community Health
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA075169; United States / NCI NIH HHS / CA / R01 CA75169
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vitamins
  •  go-up   go-down


47. Imanishi H, Okamura N, Yagi M, Noro Y, Moriya Y, Nakamura T, Hayakawa A, Takeshima Y, Sakaeda T, Matsuo M, Okumura K: Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet; 2007;52(2):166-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma.
  • Methotrexate is administered in high doses to treat childhood acute lymphoblastic leukemia and malignant lymphoma.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Liver Diseases / genetics. Lymphoma / genetics. Methotrexate / therapeutic use. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


48. Palermo CM, Bennett CA, Winters AC, Hemenway CS: The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cells. Leuk Res; 2008 Apr;32(4):633-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cells.
  • Despite ongoing success in the treatment of childhood acute lymphoblastic leukemia, patients harboring translocations involving the MLL gene at chromosome 11q23 remain resistant to treatment.
  • PFWT induced cell death in leukemia cells expressing MLL-AF4 with little effect on the colony forming potential of hematopoietic progenitor cells, suggesting the AF4-AF9 complex is an important pharmacological target for leukemia therapy and PFWT is a promising chemotherapeutic prototype.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurobiol Aging. 2000 May-Jun;21(3):383-421 [10858586.001]
  • [Cites] Cell Death Differ. 2005 Sep;12(9):1219-24 [16094402.001]
  • [Cites] Leukemia. 2000 Oct;14(10):1833-49 [11021759.001]
  • [Cites] Mutat Res. 2000 Nov 20;455(1-2):111-27 [11113471.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):439-44 [11212227.001]
  • [Cites] Mol Cell. 2001 Sep;8(3):613-21 [11583623.001]
  • [Cites] J Biol Chem. 2002 Jan 4;277(1):432-8 [11606597.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):153-66 [11950215.001]
  • [Cites] Lancet. 2002 Jun 1;359(9321):1909-15 [12057554.001]
  • [Cites] Pharmacol Res. 2003 Apr;47(4):355-62 [12644394.001]
  • [Cites] Prostate. 2003 May 1;55(2):147-57 [12661040.001]
  • [Cites] Cell Death Differ. 2003 Oct;10(10):1204-12 [14502243.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7414-30 [14576849.001]
  • [Cites] Leukemia. 2004 Jan;18(1):92-102 [14603337.001]
  • [Cites] Leukemia. 2004 Feb;18(2):227-32 [14671638.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2299-307 [14645012.001]
  • [Cites] Genes Dev. 2004 May 1;18(9):965-74 [15132992.001]
  • [Cites] Genes Dev. 2004 Jun 1;18(11):1272-82 [15145826.001]
  • [Cites] Cell Death Differ. 2004 Aug;11(8):937-9 [15044964.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Aug;310(2):425-36 [15075382.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1364-72 [15269783.001]
  • [Cites] Pharmacol Rev. 1972 Dec;24(4):583-655 [4565956.001]
  • [Cites] Blood. 1987 Jul;70(1):192-9 [3496132.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 1;88(9):3671-5 [2023917.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 15;90(10):4631-5 [8506309.001]
  • [Cites] Br J Haematol. 1997 Jul;98(1):157-69 [9233580.001]
  • [Cites] Leukemia. 1997 Sep;11(9):1469-77 [9305600.001]
  • [Cites] Am J Pathol. 1997 Nov;151(5):1205-13 [9358745.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1561-4 [9766500.001]
  • [Cites] Curr Biol. 1999 Sep 9;9(17):967-70 [10508592.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1605-12 [16034464.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2005 Nov;37(11):719-27 [16270150.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2296-303 [16208414.001]
  • [Cites] Exp Cell Res. 2006 Jan 1;312(1):27-39 [16288739.001]
  • [Cites] Infect Immun. 2007 Apr;75(4):1984-93 [17283090.001]
  • [Cites] Curr Opin Immunol. 2003 Oct;15(5):553-9 [14499264.001]
  • [Cites] Leukemia. 1999 Oct;13(10):1539-47 [10516755.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:80-97 [15561678.001]
  • [Cites] Infect Immun. 2005 Apr;73(4):1907-16 [15784530.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3155-62 [15867207.001]
  • [Cites] Trends Neurosci. 2000 Sep;23(9):410-1 [10941188.001]
  • (PMID = 17875318.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098459-03; United States / NCI NIH HHS / CA / CA098459-03; United States / NCI NIH HHS / CA / CA098459-03S1; United States / NCRR NIH HHS / RR / P20 RR020152; United States / NCI NIH HHS / CA / CA 098459; United States / NCI NIH HHS / CA / R01 CA098459-03S2; United States / NCI NIH HHS / CA / R01 CA098459; United States / NCRR NIH HHS / RR / P20 RR020152-037527; United States / NCI NIH HHS / CA / R01 CA098459-03S1; United States / NCRR NIH HHS / RR / RR 020152; United States / NCI NIH HHS / CA / F32 CA 119474; United States / NCI NIH HHS / CA / F32 CA119474; United States / NCRR NIH HHS / RR / RR020152-037527; United States / NCI NIH HHS / CA / CA098459-03S2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MLL-AF4 fusion protein, human; 0 / MLLT3 protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Peptide Fragments; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  • [Other-IDs] NLM/ NIHMS41852; NLM/ PMC2270790
  •  go-up   go-down


49. Luo XQ, Ke ZY, Guan XQ, Zhang YC, Huang LB, Zhu J: The comparison of outcome and cost of three protocols for childhood non-high risk acute lymphoblastic leukemia in China. Pediatr Blood Cancer; 2008 Aug;51(2):204-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The comparison of outcome and cost of three protocols for childhood non-high risk acute lymphoblastic leukemia in China.
  • OBJECTIVE: To compare the outcome and treatment cost of three protocols for childhood non-high risk acute lymphoblastic leukemia (ALL), and evaluate the feasibility of less intensive treatment protocol for low income families.
  • RESULTS: Among 243 patients, 19 abandoned treatment, 3 transferred to other hospitals, 48 were high-risk and were treated with the high risk protocol, and 4 had mature B-ALL.
  • A total of 169 cases were enrolled on non-high risk protocols: 46 treated on China-98 protocol, 73 on modified ALLIC BFM2002 and 50 from low income families on Economic Protocol.
  • The reduced intensity protocol appears to achieve reasonable EFS (72.8% at 4 years) for non-high risk ALL at a much lower cost.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


50. Boublikova L, Kalinova M, Ryan J, Quinn F, O'Marcaigh A, Smith O, Browne P, Stary J, McCann SR, Trka J, Lawler M: Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia; 2006 Feb;20(2):254-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
  • Wilms' tumor gene 1 (WT1) is overexpressed in the majority (70-90%) of acute leukemias and has been identified as an independent adverse prognostic factor, a convenient minimal residual disease (MRD) marker and potential therapeutic target in acute leukemia.
  • We examined WT1 expression patterns in childhood acute lymphoblastic leukemia (ALL), where its clinical implication remains unclear.
  • Using a real-time quantitative PCR designed according to Europe Against Cancer Program recommendations, we evaluated WT1 expression in 125 consecutively enrolled patients with childhood ALL (106 BCP-ALL, 19 T-ALL) and compared it with physiologic WT1 expression in normal and regenerating bone marrow (BM).
  • In childhood B-cell precursor (BCP)-ALL, we detected a wide range of WT1 levels (5 logs) with a median WT1 expression close to that of normal BM.
  • WT1 expression in childhood T-ALL was significantly higher than in BCP-ALL (P<0.001).
  • Patients with MLL-AF4 translocation showed high WT1 overexpression (P<0.01) compared to patients with other or no chromosomal aberrations.
  • Analysis of relapsed cases (14/125) indicated that an abnormal increase or decrease in WT1 expression was associated with a significantly increased risk of relapse (P=0.0006), and this prognostic impact of WT1 was independent of other main risk factors (P=0.0012).
  • In summary, our study suggests that WT1 expression in childhood ALL is very variable and much lower than in AML or adult ALL.
  • WT1, thus, will not be a useful marker for MRD detection in childhood ALL, however, it does represent a potential independent risk factor in childhood ALL.
  • Interestingly, a proportion of childhood ALL patients express WT1 at levels below the normal physiological BM WT1 expression, and this reduced WT1 expression appears to be associated with a higher risk of relapse.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Molecular Diagnostic Techniques / methods. Neoplasm, Residual / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. WT1 Proteins / genetics


51. Gregers J, Christensen IJ, Dalhoff K, Lausen B, Schroeder H, Rosthoej S, Carlsen N, Schmiegelow K, Peterson C: The association of reduced folate carrier 80G&gt;A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood; 2010 Jun 10;115(23):4671-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number.
  • The RFC gene (SLC19A1) is located on chromosome 21, and we hypothesized that the RFC80 G>A polymorphism would affect outcome and toxicity in childhood leukemia and that this could interact with chromosome 21 copy number in the leukemic clone.
  • A total of 500 children with acute lymphoblastic leukemia treated according to the common Nordic treatment protocols were included, and we found that the RFC AA variant was associated with a 50% better chance of staying in remission compared with GG or GA variants (P = .046).
  • [MeSH-major] Aneuploidy. Chromosomes, Human, Pair 21 / genetics. Membrane Transport Proteins / genetics. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma


52. Gaipa G, Basso G, Maglia O, Leoni V, Faini A, Cazzaniga G, Bugarin C, Veltroni M, Michelotto B, Ratei R, Coliva T, Valsecchi MG, Biondi A, Dworzak MN, I-BFM-ALL-FCM-MRD Study Group: Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia; 2005 Jan;19(1):49-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection.
  • However, we previously noticed modulation of surface antigen expression in acute lymphoblastic leukemia (ALL) during the early treatment.
  • [MeSH-major] Neoplasm, Residual. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2005 Oct;19(10):1858 [16107890.001]
  • [CommentIn] Leukemia. 2005 Oct;19(10):1845-7 [16107891.001]
  • (PMID = 15538405.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


53. Robazzi TC, Silva LR, Mendonça N, Barreto JH: Gastrointestinal manifestations as initial presentation of acute leukemias in children and adolescents. Acta Gastroenterol Latinoam; 2008 Jun;38(2):126-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal manifestations as initial presentation of acute leukemias in children and adolescents.
  • OBJECTIVE: this study aimed to determine the prevalence and characteristics of gastrointestinal manifestations on initial clinical presentation of acute leukemias (AL) in childhood.
  • RESULTS: acute lymphoid leukemia (ALL) was diagnosed in 273 (77.1%) patients and acute non-lymphocytic leukemia (AML) in 81 (22.9%).
  • CONCLUSIONS: gastrointestinal symptoms are not very well-documented as initial manifestation of leukemia in children and should be considered on the differential diagnosis of gastrointestinal symptoms of unknown etiology in children.
  • [MeSH-major] Gastrointestinal Diseases / etiology. Leukemia, Myeloid, Acute / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697407.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


54. van der Velden VH, Panzer-Grümayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A, Basso G, Schrappe M, Wijkhuijs JM, Konrad M, Bartram CR, Masera G, Biondi A, van Dongen JJ: Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia; 2007 Apr;21(4):706-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting.
  • Minimal residual disease (MRD) diagnostics is used for treatment stratification in childhood acute lymphoblastic leukemia.
  • [MeSH-major] Neoplasm, Residual / genetics. Polymerase Chain Reaction / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


55. Lee DS, Kim YR, Cho HK, Lee CK, Lee JH, Cho HI: The presence of TEL/AML1 rearrangement and cryptic deletion of the TEL gene in adult acute lymphoblastic leukemia (ALL). Cancer Genet Cytogenet; 2005 Oct 15;162(2):176-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The presence of TEL/AML1 rearrangement and cryptic deletion of the TEL gene in adult acute lymphoblastic leukemia (ALL).
  • TEL/AML1 (also known as ETV6/RUNX1) rearrangement is the most frequent genetic change in childhood B-acute lymphoblastic leukemia (ALL) and is associated with a favorable prognosis.
  • TEL/AML1 rearrangement is not unique in childhood ALL, and cryptic TEL deletion without TEL/AML1 rearrangement was more frequent than the TEL/AML1 rearrangement in adult ALL.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Deletion. Gene Rearrangement. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16213368.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / ETS translocation variant 6 protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


56. Chowdhury S, Mandal C: O-acetylated sialic acids: multifaceted role in childhood acute lymphoblastic leukaemia. Biotechnol J; 2009 Mar;4(3):361-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] O-acetylated sialic acids: multifaceted role in childhood acute lymphoblastic leukaemia.
  • Childhood acute lymphoblastic leukaemia (ALL), a malignant transformation of the lymphoblasts, is highly responsive to chemotherapy.
  • To address this question, the present review deals with the induction of an unique O-acetyl derivative of sialic acid on a few disease-associated glycoproteins and glycolipids at the onset of childhood ALL, a finding of our group in the last decade.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Sialic Acids / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19296441.001).
  • [ISSN] 1860-7314
  • [Journal-full-title] Biotechnology journal
  • [ISO-abbreviation] Biotechnol J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Epitopes; 0 / Glycolipids; 0 / Glycoproteins; 0 / Sialic Acids
  • [Number-of-references] 57
  •  go-up   go-down


57. Guo Y, Chen YM, Zou Y, Chen XJ, Zhang L, Wang SC, Zhu XF: [Biologic features of 688 cases of childhood acute leukemia-a single centre retrospective study]. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Oct;11(10):793-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biologic features of 688 cases of childhood acute leukemia-a single centre retrospective study].
  • OBJECTIVE: To investigate the biologic features of childhood acute leukemia in the northern region of China through a small cohort study in a single center.
  • METHODS: The medical records of 688 children with acute leukemia (age< or =15 years) who were initially diagnosed at Blood Disease Hospital of Chinese Academy of Medical Sciences from October 2003 to June 2006 were retrospectively studied.
  • RESULTS: Four hundred children were diagnosed as acute lymphoblastic leukemia (ALL), with a peak incidence at ages of 1-4 years.
  • Two hundred and twenty-two children were diagnosed as acute myeloid leukemia (AML), with a peak incidence at ages of 10-15 years.
  • Acute hybrid leukemia (AHL) was confirmed in 24 children (4.2%), with a median age of 9 years.
  • Seventy-four percent of the children with (AHL) had mainly CD13 and CD33 expression in myeloid antigen integral.
  • CONCLUSIONS: There are differences in the biologic features of childhood acute leukemia between the northern region of China and other regions and races, which suggests that there might be differences in the pathogenesis of childhood acute leukemia in different environmental exposures.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19849934.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


58. Porto L, Preibisch C, Hattingen E, Bartels M, Lehrnbecher T, Dewitz R, Zanella F, Good C, Lanfermann H, DuMesnil R, Kieslich M: Voxel-based morphometry and diffusion-tensor MR imaging of the brain in long-term survivors of childhood leukemia. Eur Radiol; 2008 Nov;18(11):2691-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Voxel-based morphometry and diffusion-tensor MR imaging of the brain in long-term survivors of childhood leukemia.
  • The aims of this study were to detect morphological changes in neuroanatomical components in adult survivors of acute lymphoblastic leukemia (ALL).
  • Voxel-based morphometry (VBM) can be used to detect subtle structural changes in brain morphology and via analysis of fractional anisotropy (FA), diffusion-tensor imaging (DTI) can non-invasively probe white matter (WM) integrity.
  • Ten ALL survivors received chemotherapy and irradiation; ten survivors received chemotherapy alone during childhood.
  • Survivors of childhood ALL who underwent cranial irradiation during childhood had smaller WM volumes and reduced GM concentration within the caudate nucleus and thalamus.
  • [MeSH-major] Brain / pathology. Diffusion Magnetic Resonance Imaging / methods. Imaging, Three-Dimensional / methods. Leukemia / diagnosis

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dis Child. 2003 Feb;88(2):147-50 [12538320.001]
  • [Cites] Radiology. 2003 Dec;229(3):659-69 [14576448.001]
  • [Cites] Pediatr Blood Cancer. 2005 May;44(5):478-86 [15918215.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Oct;26(9):2371-7 [16219848.001]
  • [Cites] J Pediatr Psychol. 2001 Jan-Feb;26(1):1-9 [11145727.001]
  • [Cites] Med Pediatr Oncol. 2000 Nov;35(5):456-61 [11070477.001]
  • [Cites] Magn Reson Med. 1996 Jan;35(1):56-61 [8771022.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 May;26(5):1263-9 [15891195.001]
  • [Cites] Magn Reson Med. 1995 Jul;34(1):65-73 [7674900.001]
  • [Cites] Med Pediatr Oncol. 2002 May;38(5):320-8 [11979456.001]
  • [Cites] NMR Biomed. 2003 Aug;16(5):257-60 [14648885.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1989 Spring;11(1):93-105 [2653080.001]
  • [Cites] Cancer. 2003 May 15;97(10):2512-9 [12733151.001]
  • [Cites] Neuroimage. 2003 Jan;18(1):127-42 [12507450.001]
  • [Cites] J Magn Reson Imaging. 2001 Apr;13(4):534-46 [11276097.001]
  • [Cites] J Child Neurol. 2005 Feb;20(2):129-33 [15794179.001]
  • [Cites] Glia. 1996 Jun;17(2):83-93 [8776576.001]
  • [Cites] Neuroimage. 2004 Feb;21(2):757-67 [14980579.001]
  • [Cites] Prog Neurobiol. 2005 Apr;75(5):321-41 [15913880.001]
  • [Cites] NMR Biomed. 2002 Nov-Dec;15(7-8):543-52 [12489100.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):941-9 [16411228.001]
  • [Cites] Neuroimage. 2001 Sep;14(3):685-700 [11506541.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1975 Aug;38(8):810-5 [1058923.001]
  • [Cites] J Neurosci. 2005 Nov 16;25(46):10729-39 [16291946.001]
  • [Cites] Neuroimage. 2005 Jul 15;26(4):1164-73 [15961051.001]
  • [Cites] Neuroimage. 2002 Jan;15(1):273-89 [11771995.001]
  • [Cites] Hum Brain Mapp. 2000 Jul;10(3):120-31 [10912591.001]
  • [Cites] J Magn Reson B. 1994 Mar;103(3):247-54 [8019776.001]
  • [Cites] Swiss Med Wkly. 2001 Apr 7;131(13-14):180-7 [11345808.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):12-9 [15701278.001]
  • [Cites] Cereb Cortex. 2005 Dec;15(12):1848-54 [15758200.001]
  • [Cites] Annu Rev Neurosci. 1986;9:357-81 [3085570.001]
  • [Cites] Neuroimage. 2006 Jan 15;29(2):493-504 [16194615.001]
  • [Cites] Dev Neuropsychol. 2002;21(2):173-95 [12139198.001]
  • [Cites] Neuroimage. 2000 Jun;11(6 Pt 1):805-21 [10860804.001]
  • [Cites] Neuroimage. 2001 Dec;14(6):1238-43 [11707080.001]
  • (PMID = 18491104.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


59. Riedt T, Ebinger M, Salih HR, Tomiuk J, Handgretinger R, Kanz L, Grünebach F, Lengerke C: Aberrant expression of the homeobox gene CDX2 in pediatric acute lymphoblastic leukemia. Blood; 2009 Apr 23;113(17):4049-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of the homeobox gene CDX2 in pediatric acute lymphoblastic leukemia.
  • Consistent with the notion that embryonic pathways can reactivate during adult oncogenesis, recent studies suggest involvement of CDX2 in human acute myeloid leukemia (AML).
  • Analysis of a cohort of 37 childhood acute lymphoblastic leukemia (ALL) patients treated in our hospital reveals that high CDX2 expression levels at diagnosis correlate with persistence of minimal residual disease (MRD) during the course of treatment.
  • Thus, CDX2 expression levels may serve as a marker for adverse prognosis in pediatric ALL.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / genetics. Homeodomain Proteins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19218548.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


60. Christensen MS, Heyman M, Möttönen M, Zeller B, Jonmundsson G, Hasle H, Nordic Society of Paediatric Haematology and Oncology (NOPHO): Treatment-related death in childhood acute lymphoblastic leukaemia in the Nordic countries: 1992-2001. Br J Haematol; 2005 Oct;131(1):50-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment-related death in childhood acute lymphoblastic leukaemia in the Nordic countries: 1992-2001.
  • Despite continuously more successful treatment of childhood acute lymphoblastic leukaemia (ALL), 2-5% of children still die of other causes than relapse.
  • Infections still remain a major challenge in childhood ALL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16173962.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


61. Wiemels JL, Zhang Y, Chang J, Zheng S, Metayer C, Zhang L, Smith MT, Ma X, Selvin S, Buffler PA, Wiencke JK: RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia. Leukemia; 2005 Mar;19(3):415-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia.
  • We explored the relationship of RAS gene mutations with epidemiologic and cytogenetic factors in a case series of children with leukemia.
  • Diagnostic bone marrow samples from 191 incident leukemia cases from the Northern California Childhood Leukemia Study were typed for NRAS and KRAS codon 12 and 13 mutations.
  • Among the 142 B-cell acute lymphoblastic leukemia (ALL) cases, RAS mutations were more common among Hispanic children (P=0.11) or children born to mothers <30 years (P=0.007).
  • Interestingly, smoking of the father in the 3 months prior to pregnancy was reported less frequently among hyperdiploid leukemia patients than among those without hyperdiploidy (P=0.02).
  • The data suggest that RAS and high hyperdiploidy may be cooperative genetic events to produce the leukemia subtype; and furthermore, that maternal age and paternal preconception smoking or other factors associated with these parameters are critical in the etiology of subtypes of childhood leukemia.
  • [MeSH-major] Genes, ras / genetics. Mutation. Polyploidy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15674422.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCHHSTP CDC HHS / PS / PS42 ES04705; United States / NCI NIH HHS / CA / R01 CA89032; United States / NIEHS NIH HHS / ES / R01 ES09137
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


62. Kawaguchi H, Taketani T, Hongo T, Park MJ, Koh K, Ida K, Kobayashi M, Takita J, Taki T, Yoshino H, Bessho F, Hayashi Y: In vitro drug resistance to imatinib and mutation of ABL gene in childhood Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Leuk Lymphoma; 2005 Feb;46(2):273-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro drug resistance to imatinib and mutation of ABL gene in childhood Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
  • Imatinib, the ABL kinase inhibitor, is used not only for Philadelphia chromosome-positive (Ph + ) chronic myelogenous leukemia, but also for Ph + acute lymphoblastic leukemia (ALL), although resistance to the drug tends to develop in an early stage of the clinical course.
  • We describe a childhood refractory Ph + ALL patient in whom progressive resistance to imatinib was correlated with the appearance of a mutation in the BCR-ABL kinase domain and in vitro drug resistance to imatinib as determined by the methyl-thiazol-tetrazolium (MTT) assay.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Genes, abl / genetics. Mutation, Missense. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / therapeutic use


63. Rhein P, Scheid S, Ratei R, Hagemeier C, Seeger K, Kirschner-Schwabe R, Moericke A, Schrappe M, Spang R, Ludwig WD, Karawajew L: Gene expression shift towards normal B cells, decreased proliferative capacity and distinct surface receptors characterize leukemic blasts persisting during induction therapy in childhood acute lymphoblastic leukemia. Leukemia; 2007 May;21(5):897-905
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression shift towards normal B cells, decreased proliferative capacity and distinct surface receptors characterize leukemic blasts persisting during induction therapy in childhood acute lymphoblastic leukemia.
  • In childhood acute lymphoblastic leukemia (ALL), persistence of leukemic blasts during therapy is of crucial prognostic significance.
  • [MeSH-major] B-Lymphocytes / metabolism. Blast Crisis / metabolism. Gene Expression Profiling. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17330098.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD11b; 0 / Receptors, Interferon; 0 / interferon gamma receptor; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


64. Lee KM, Ward MH, Han S, Ahn HS, Kang HJ, Choi HS, Shin HY, Koo HH, Seo JJ, Choi JE, Ahn YO, Kang D: Paternal smoking, genetic polymorphisms in CYP1A1 and childhood leukemia risk. Leuk Res; 2009 Feb;33(2):250-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paternal smoking, genetic polymorphisms in CYP1A1 and childhood leukemia risk.
  • We conducted a case-control study to evaluate the association between paternal smoking and childhood leukemia and to evaluate potential modification by polymorphisms in CYP1A1.
  • Histologically confirmed childhood leukemia cases (n=164) and non-cancer controls (n=164) were recruited from three teaching hospitals in Seoul, Korea.
  • We also conducted a meta-analysis of 12 studies that have reported the association between paternal smoking and childhood leukemia risk.
  • Paternal smoking at home was associated with all leukemias (OR=1.8, 95% CI=1.1-2.8) and acute lymphoblastic leukemia (ALL) (2.0, 1.2-3.4).
  • The meta-analysis showed that overall paternal smoking (1.13, 1.04-1.24) and smoking before the pregnancy of the child (1.12, 1.04-1.21) were significantly associated with childhood leukemia risk.
  • Our results suggest that paternal smoking is a risk factor for childhood leukemia and the effect may be modified by CYP1A1 genotype.
  • [MeSH-major] Cytochrome P-450 CYP1A1 / genetics. Fathers. Leukemia / etiology. Polymorphism, Genetic. Smoking / adverse effects
  • [MeSH-minor] Adolescent. Case-Control Studies. Child. Child, Preschool. Environmental Exposure. Female. Genotype. Haplotypes. Humans. Infant. Male. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Risk Factors


65. Cole PD, Beckwith KA, Vijayanathan V, Roychowdhury S, Smith AK, Kamen BA: Folate homeostasis in cerebrospinal fluid during therapy for acute lymphoblastic leukemia. Pediatr Neurol; 2009 Jan;40(1):34-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Folate homeostasis in cerebrospinal fluid during therapy for acute lymphoblastic leukemia.
  • The neurotoxic effects of therapy for childhood acute lymphoblastic leukemia can result in leukoencephalopathy or measurable deficits in cognitive function.
  • With the objective of identifying such predictors, cerebrospinal fluid collected from 53 patients over 2.5 years of therapy for childhood acute lymphoblastic leukemia was retrospectively studied.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Biomarkers, Tumor / cerebrospinal fluid. Cognition / drug effects. Folic Acid / cerebrospinal fluid. Homeostasis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / cerebrospinal fluid. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMINOPTERIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068252.001).
  • [ISSN] 0887-8994
  • [Journal-full-title] Pediatric neurology
  • [ISO-abbreviation] Pediatr. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Folic Acid Antagonists; 0 / tau Proteins; 0LVT1QZ0BA / Homocysteine; 935E97BOY8 / Folic Acid; JYB41CTM2Q / Aminopterin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


66. Goubin A, Auclerc MF, Auvrignon A, Patte C, Bergeron C, Hémon D, Clavel J: Survival in France after childhood acute leukaemia and non-Hodgkin's lymphoma (1990-2000). Eur J Cancer; 2006 Mar;42(4):534-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival in France after childhood acute leukaemia and non-Hodgkin's lymphoma (1990-2000).
  • This article describes the survival after childhood acute leukaemia (AL) and non-Hodgkin's lymphoma (NHL) of French population aged less than 15 years.
  • The French National Registry of Childhood Leukaemia and Lymphoma recorded 3995 cases of acute lymphoblastic leukaemia (ALL), 812 of acute myeloid leukaemia (AML) and 1137 of NHL over the period from 1990 to 2000.
  • The results reported herein are similar to those reported by other European registries and clinical trials.
  • [MeSH-major] Lymphoma, Non-Hodgkin / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16412629.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


67. Lönnerholm G, Frost BM, Söderhäll S, de Graaf SS: Vincristine pharmacokinetics in children with Down syndrome. Pediatr Blood Cancer; 2009 Jan;52(1):123-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Children with Down syndrome (DS), who represent about 2% of childhood acute lymphoblastic leukemia, have inferior prognosis compared to non-DS children.
  • For vincristine (and many other anticancer agents) pharmacokinetic data are scant or missing, and there is considerable uncertainty about the optimal dosing of drugs to patients with DS.
  • We studied vincristine pharmacokinetics on treatment day one in six children with DS and compared to 92 non-DS children.
  • [MeSH-major] Down Syndrome / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Vincristine / pharmacokinetics

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Blood Cancer. 2009 Jan;52(1):1-2 [18816806.001]
  • (PMID = 18615507.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine
  •  go-up   go-down


68. Tang JY, Gu LJ, Xue HL, Chen J, Pan C, Wu WT, Shen SH, Dong L, Zhou M, Ye QD, Jiang H: [Report on induction efficacy of protocol ALL-2005 and middle term follow-up of 158 cases of childhood acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2009 May;30(5):289-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Report on induction efficacy of protocol ALL-2005 and middle term follow-up of 158 cases of childhood acute lymphoblastic leukemia].
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19799121.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


69. van Delft FW, Bellotti T, Luo Z, Jones LK, Patel N, Yiannikouris O, Hill AS, Hubank M, Kempski H, Fletcher D, Chaplin T, Foot N, Young BD, Hann IM, Gammerman A, Saha V: Prospective gene expression analysis accurately subtypes acute leukaemia in children and establishes a commonality between hyperdiploidy and t(12;21) in acute lymphoblastic leukaemia. Br J Haematol; 2005 Jul;130(1):26-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective gene expression analysis accurately subtypes acute leukaemia in children and establishes a commonality between hyperdiploidy and t(12;21) in acute lymphoblastic leukaemia.
  • We have prospectively analysed and correlated the gene expression profiles of children presenting with acute leukaemia to the Royal London and Great Ormond Street Hospitals with morphological diagnosis, immunophenotype and karyotype.
  • Total RNA extracted from freshly sorted blast cells was obtained from 84 lymphoblastic [acute lymphoblastic leukaemia (ALL)], 20 myeloid [acute myeloid leukaemia (AML)] and three unclassified acute leukaemias and hybridised to the high density Affymetrix U133A oligonucleotide array.
  • A novel 50-gene set accurately identified all patients with ALL and AML and predicted for a diagnosis of AML in three patients with unclassified acute leukaemia.
  • A unique gene set was derived for each of eight subtypes of acute leukaemia within our data set.
  • Our analyses demonstrate that not only is microarray analysis the single most effective tool for the diagnosis of acute leukaemias of childhood but it has the ability to identify unique biological pathways.
  • To further evaluate its prognostic value it needs to be incorporated into the routine diagnostic analysis for large-scale clinical trials in childhood acute leukaemias.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 12. Chromosomes, Human, Pair 21. Gene Expression Profiling. Oligonucleotide Array Sequence Analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Acute Disease. Analysis of Variance. Child. Chromosome Banding. Core Binding Factor Alpha 2 Subunit. DNA-Binding Proteins / genetics. Diagnosis, Differential. Gene Rearrangement. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Karyotyping. Leukemia / genetics. Leukemia, Myeloid / diagnosis. Leukemia, Myeloid / genetics. Nuclear Proteins / genetics. Ploidies. Principal Component Analysis. Prospective Studies. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-ets. Repressor Proteins / genetics. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction. Telomeric Repeat Binding Protein 2 / genetics. Transcription Factors / genetics. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982341.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 14840
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / DNA-Binding Proteins; 0 / ETS translocation variant 6 protein; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-ets; 0 / RUNX1 protein, human; 0 / Repressor Proteins; 0 / Telomeric Repeat Binding Protein 2; 0 / Transcription Factors
  •  go-up   go-down


70. Ociepa T, Maloney E, Kamieńska E, Wysocki M, Kurylak A, Matysiak M, Urasiński T, Urasińska E, Domagała W: Simultaneous assessment of p53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia. Pol J Pathol; 2010;61(4):199-205
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous assessment of p53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia.
  • Ineffective apoptosis is one of main causes of a treatment failure in childhood acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Leukocytes, Mononuclear / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Prednisone / therapeutic use. Proto-Oncogene Proteins c-mdm2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21290342.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2; VB0R961HZT / Prednisone
  •  go-up   go-down


71. Pereira TV, Rudnicki M, Pereira AC, Pombo-de-Oliveira MS, Franco RF: 5,10-Methylenetetrahydrofolate reductase polymorphisms and acute lymphoblastic leukemia risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev; 2006 Oct;15(10):1956-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5,10-Methylenetetrahydrofolate reductase polymorphisms and acute lymphoblastic leukemia risk: a meta-analysis.
  • There is evidence supporting a role for 5-10 methylenetetrahydrofolate reductase (MTHFR) gene variants in acute lymphoblastic leukemia (ALL).
  • The meta-analysis of the C677T polymorphism and risk of childhood ALL included 13 studies with a total of 4,894 individuals.
  • Under a fixed-effects model, the TT genotype failed to be associated with a statistically significant reduction of childhood ALL risk (TT versus CT + CC: OR, 0.88; 95% CI, 0.73-1.06; P = 0.18).
  • No association between the A1298C variant and susceptibility to both adult and childhood ALL was disclosed.
  • Our findings support the proposal that the common genetic C677T polymorphism in the MTHFR contributes to the risk of adult ALL, but not to the childhood ALL susceptibility.
  • [MeSH-major] Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17035405.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  • [Number-of-references] 39
  •  go-up   go-down


72. Hovén E, Anclair M, Samuelsson U, Kogner P, Boman KK: The influence of pediatric cancer diagnosis and illness complication factors on parental distress. J Pediatr Hematol Oncol; 2008 Nov;30(11):807-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of pediatric cancer diagnosis and illness complication factors on parental distress.
  • METHODS: We used a model in which "complicated childhood cancers" were grouped into 1 category, after identifying a set of potentially influential illness complication variables.
  • This category included central nervous system tumors, acute myeloid leukemia, and bone tumors.
  • Parental distress in that category (n=144) was compared with distress after acute lymphoblastic leukemia (n=177) in the child.
  • RESULTS: Parents in the complicated cancer category showed significantly heightened disease-related fear, anxiety, depression, loss of control, late effects-related uncertainty, and poorer self-esteem compared with parents of children with acute lymphoblastic leukemia.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • MedlinePlus Health Information. consumer health - Stress.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18989157.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. van Scherpenzeel Thim V, Remacle S, Picard J, Cornu G, Gofflot F, Rezsohazy R, Verellen-Dumoulin C: Mutation analysis of the HOX paralogous 4-13 genes in children with acute lymphoid malignancies: identification of a novel germline mutation of HOXD4 leading to a partial loss-of-function. Hum Mutat; 2005 Apr;25(4):384-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation analysis of the HOX paralogous 4-13 genes in children with acute lymphoid malignancies: identification of a novel germline mutation of HOXD4 leading to a partial loss-of-function.
  • The molecular basis of susceptibility to childhood malignant hemopathy remains largely unknown.
  • We aimed to explore the possibility that germline alterations of HOX genes might be involved in childhood acute lymphoid malignancies.
  • A cohort of 86 children diagnosed with acute lymphoid malignancy was studied, 20 of them concurrently presenting a congenital anomaly of the skeleton.
  • Subsequently, we extended the HOX mutation screening to the other 66 children having a malignant lymphoproliferative disorder, but without skeletal defects.
  • While 13 changes were also observed in healthy controls, three variants were exclusively found in acute lymphoid malignancy cases.
  • These comprised the germline c.242A>T (p.Glu81Val) missense mutation of HOXD4, detected in two children diagnosed with acute lymphoblastic leukemia (ALL).
  • Furthermore, this mutation was found in association with other specific HOX variants of cluster D (2q31-q37), defining a unique haplotype.
  • The p.Glu81Val mutation of HOXD4 thus results in a partial loss-of-function, which might be involved in childhood ALL.
  • [MeSH-major] Germ-Line Mutation. Homeodomain Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Transcription Factors / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15776434.001).
  • [ISSN] 1098-1004
  • [Journal-full-title] Human mutation
  • [ISO-abbreviation] Hum. Mutat.
  • [Language] eng
  • [Databank-accession-numbers] OMIM/ 142981; RefSeq/ NM/ 014621
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HOXD1 protein, human; 0 / Homeodomain Proteins; 0 / Hoxd4 protein, mouse; 0 / Transcription Factors
  •  go-up   go-down


74. Best A, Matheson E, Minto L, Hall AG, Irving JA: Mismatch repair and the downstream target genes, PAX5 and Ikaros, in childhood acute lymphoblastic leukemia. Leuk Res; 2010 Aug;34(8):1098-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mismatch repair and the downstream target genes, PAX5 and Ikaros, in childhood acute lymphoblastic leukemia.
  • [MeSH-major] B-Cell-Specific Activator Protein / genetics. DNA Mismatch Repair / genetics. Ikaros Transcription Factor / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Zebrafish Proteins / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20233627.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / BAX protein, human; 0 / IKZF1 protein, human; 0 / RNA, Messenger; 0 / Receptors, Transforming Growth Factor beta; 0 / Zebrafish Proteins; 0 / bcl-2-Associated X Protein; 0 / pax5 protein, zebrafish; 148971-36-2 / Ikaros Transcription Factor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


75. Stanulla M, Schrappe M: Treatment of childhood acute lymphoblastic leukemia. Semin Hematol; 2009 Jan;46(1):52-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of childhood acute lymphoblastic leukemia.
  • Childhood acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood.
  • Studies in ALL have been a model for clinical and basic research beyond pediatric hemato-oncology.
  • As a result of sustained and well-organized research efforts since the early 1960s, childhood ALL now can be successfully treated in about 80% of patients by the application of intensive combination chemotherapy regimens, which in specific patient subgroups may need to be supplemented with radiation therapy and/or hematopoietic stem cell transplantation.
  • Thus, future research must extend our molecular understanding of leukemia and host factors in order to even more specifically identify the mechanisms underlying the differences in treatment response and outcome, and to finally address the therapeutic needs of the individual child.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


76. Wasim M, Carlet M, Mansha M, Greil R, Ploner C, Trockenbacher A, Rainer J, Kofler R: PLZF/ZBTB16, a glucocorticoid response gene in acute lymphoblastic leukemia, interferes with glucocorticoid-induced apoptosis. J Steroid Biochem Mol Biol; 2010 Jun;120(4-5):218-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PLZF/ZBTB16, a glucocorticoid response gene in acute lymphoblastic leukemia, interferes with glucocorticoid-induced apoptosis.
  • Glucocorticoids (GCs) cause cell cycle arrest and apoptosis in lymphoid cells which is exploited to treat lymphoid malignancies.
  • We previously defined a list of GC-regulated genes by expression profiling in children with acute lymphoblastic leukemia (ALL) during systemic GC monotherapy and in experimental systems of GC-induced apoptosis.
  • To investigate its role in the anti-leukemic GC effects, we performed overexpression and knock-down experiments in CCRF-CEM childhood ALL cells.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Gene Expression Regulation, Leukemic / drug effects. Glucocorticoids / pharmacology. Kruppel-Like Transcription Factors / genetics. Kruppel-Like Transcription Factors / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • [Cites] FEBS Lett. 2006 Jul 24;580(17):4073-80 [16828757.001]
  • [Cites] Circ Res. 2006 Dec 8;99(12):1355-66 [17082479.001]
  • [Cites] Nucleic Acids Res. 1999 Oct 15;27(20):4106-13 [10497277.001]
  • [Cites] Nat Genet. 2004 Jun;36(6):647-52 [15156142.001]
  • [Cites] Nat Genet. 2004 Jun;36(6):653-9 [15156143.001]
  • [Cites] Cell Death Differ. 2004 Jul;11 Suppl 1:S45-55 [15243581.001]
  • [Cites] EMBO J. 1995 Feb 1;14(3):452-60 [7859735.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2429-37 [9395239.001]
  • [Cites] Mol Cell Endocrinol. 2009 Mar 5;300(1-2):7-16 [19000736.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11422-7 [10500192.001]
  • [Cites] J Biol Chem. 1997 Sep 5;272(36):22447-55 [9278395.001]
  • [Cites] EMBO J. 1993 Mar;12(3):1161-7 [8384553.001]
  • [Cites] Cell Death Differ. 2002 Jan;9(1):6-19 [11803370.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jun;135(2):110-9 [12127395.001]
  • [Cites] J Clin Invest. 1993 May;91(5):2260-7 [8387545.001]
  • [Cites] Leuk Res. 2010 Apr;34(4):529-34 [19631983.001]
  • [Cites] Nucl Recept. 2003 Sep 6;1(1):6 [14521715.001]
  • [Cites] Mol Hum Reprod. 2003 Oct;9(10):611-23 [12970399.001]
  • [Cites] Oncogene. 2008 Jun 19;27(27):3789-96 [18246121.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Blood. 2007 May 1;109(9):3929-35 [17218380.001]
  • [Cites] EMBO J. 1997 Jan 15;16(2):267-80 [9029148.001]
  • [Cites] J Exp Med. 2001 Mar 5;193(5):585-93 [11238589.001]
  • [Cites] Nat Protoc. 2009;4(4):495-505 [19300443.001]
  • [Cites] Stat Med. 1990 Jul;9(7):811-8 [2218183.001]
  • [Cites] Stat Appl Genet Mol Biol. 2004;3:Article3 [16646809.001]
  • [Cites] Apoptosis. 2009 Jun;14(6):821-8 [19421859.001]
  • [Cites] Science. 1995 Jun 23;268(5218):1766-9 [7792603.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jul 27;359(2):317-22 [17537403.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18694-9 [18000064.001]
  • [Cites] Mol Cell Biol. 2007 Oct;27(19):6770-81 [17664282.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9375-88 [14645547.001]
  • [Cites] Endocr Rev. 1987 May;8(2):185-234 [3038508.001]
  • [Cites] Mol Cell Biol. 2005 Jul;25(13):5552-66 [15964811.001]
  • [Cites] Oncogene. 2007 Jan 18;26(3):339-48 [16862184.001]
  • [Cites] J Immunol Methods. 1991 Jun 3;139(2):271-9 [1710634.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Apoptosis. 2007 Feb;12(2):271-91 [17191112.001]
  • [Cites] FASEB J. 2005 Mar;19(3):434-6 [15637111.001]
  • [Cites] Brief Funct Genomic Proteomic. 2007 Mar;6(1):8-18 [17384421.001]
  • [Cites] Leukemia. 2008 Feb;22(2):370-7 [18046449.001]
  • [Cites] J Steroid Biochem. 1984 Jan;20(1):1-4 [6323858.001]
  • [Cites] Leukemia. 2009 Apr;23(4):746-52 [19148136.001]
  • [Cites] Nat Genet. 2000 Jun;25(2):166-72 [10835630.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2745-54 [18417445.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):919-29 [12648060.001]
  • [Cites] Oncogene. 1999 Aug 12;18(32):4626-31 [10467407.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D46-55 [16381912.001]
  • [Cites] Oncogene. 2004 Jun 3;23(26):4567-76 [15077196.001]
  • [Cites] Gene. 1999 Aug 5;236(1):21-4 [10433962.001]
  • [Cites] Trends Endocrinol Metab. 2008 Nov;19(9):331-9 [18805703.001]
  • [Cites] Curr Top Microbiol Immunol. 2007;313:31-48 [17217037.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):348-53 [7812967.001]
  • [Cites] Cell Death Differ. 2004 Jul;11 Suppl 1:S65-72 [15017388.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):37-48 [12650700.001]
  • [Cites] Prostate. 2006 Jul 1;66(10):1092-9 [16637071.001]
  • [Cites] Blood. 2006 Mar 1;107(5):2061-9 [16293608.001]
  • [Cites] Leukemia. 2009 Apr;23(4):820-3 [19151768.001]
  • [Cites] J Allergy Clin Immunol. 2008 Feb;121(2):492-498.e10 [18036649.001]
  • (PMID = 20435142.001).
  • [ISSN] 1879-1220
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / P 18747; Austria / Austrian Science Fund FWF / / W 1101
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids; 0 / Kruppel-Like Transcription Factors; 147855-37-6 / ZBTB16 protein, human
  • [Other-IDs] NLM/ PMC2892747
  •  go-up   go-down


77. Schmitz NM, Hirt A, Aebi M, Leibundgut K: Limited redundancy in phosphorylation of retinoblastoma tumor suppressor protein by cyclin-dependent kinases in acute lymphoblastic leukemia. Am J Pathol; 2006 Sep;169(3):1074-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited redundancy in phosphorylation of retinoblastoma tumor suppressor protein by cyclin-dependent kinases in acute lymphoblastic leukemia.
  • In Nalm-6 acute lymphoblastic leukemia extracts, serine 608 is phosphorylated by CDK4/6 complexes but not by CDK2.
  • Serine 612 phosphorylation by CDK4 also occurred in extracts of childhood acute lymphoblastic leukemia cells but not in extracts of mobilized CD34+ hemopoietic progenitor cells.
  • This phenomenon could contribute to the commitment of childhood acute lymphocytic leukemia cells to proliferate and explain their refractoriness to differentiation-inducing agents.
  • [MeSH-major] Burkitt Lymphoma / metabolism. Cyclin-Dependent Kinase 2 / metabolism. Cyclin-Dependent Kinase 4 / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Protein Processing, Post-Translational. Retinoblastoma-Like Protein p107 / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Retinoblastoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Jan 27;19(4):562-70 [10698526.001]
  • [Cites] Cell. 2000 Mar 31;101(1):79-89 [10778858.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4320-3 [10969768.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Sep 7;275(3):877-84 [10973815.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19358-66 [12646568.001]
  • [Cites] Cell. 2003 Aug 22;114(4):431-43 [12941272.001]
  • [Cites] Nat Genet. 2003 Sep;35(1):25-31 [12923533.001]
  • [Cites] EMBO J. 2003 Sep 15;22(18):4794-803 [12970191.001]
  • [Cites] Curr Biol. 2003 Oct 14;13(20):1775-85 [14561402.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):27-36 [14700606.001]
  • [Cites] Biochem Biophys Res Commun. 2004 May 7;317(3):779-86 [15081408.001]
  • [Cites] Cell. 2004 Apr 16;117(2):239-51 [15084261.001]
  • [Cites] Cell. 2004 Aug 20;118(4):477-91 [15315760.001]
  • [Cites] Cell. 2004 Aug 20;118(4):493-504 [15315761.001]
  • [Cites] Science. 1989 Nov 3;246(4930):603-8 [2683075.001]
  • [Cites] Cell. 1991 May 3;65(3):381-93 [2018973.001]
  • [Cites] Cell. 1991 Oct 18;67(2):293-302 [1655277.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):6914-8 [8346196.001]
  • [Cites] Mol Cell Biol. 1993 Oct;13(10):6501-8 [8413249.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):2066-76 [8114738.001]
  • [Cites] Leukemia. 1994 Jun;8(6):940-5 [8207988.001]
  • [Cites] Cell. 1994 Jul 15;78(1):161-72 [8033208.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3215-20 [8622916.001]
  • [Cites] Cell. 2005 Dec 16;123(6):1093-106 [16360038.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14317-22 [11114185.001]
  • [Cites] Leukemia. 2001 Jan;15(1):1-9 [11243375.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(14):4773-84 [11416152.001]
  • [Cites] Nature. 2001 Sep 6;413(6851):83-6 [11544530.001]
  • [Cites] EMBO Rep. 2001 Sep;2(9):794-9 [11520855.001]
  • [Cites] J Biochem Mol Biol. 2003 Jan 31;36(1):60-5 [12542976.001]
  • [Cites] J Biol Chem. 1996 Apr 5;271(14):8313-20 [8626527.001]
  • [Cites] Mol Cell Biol. 1996 Dec;16(12):7173-81 [8943373.001]
  • [Cites] EMBO J. 1996 Dec 16;15(24):7060-9 [9003781.001]
  • [Cites] Oncogene. 1997 Jan 16;14(2):249-54 [9010227.001]
  • [Cites] Br J Haematol. 1997 Feb;96(2):366-8 [9029026.001]
  • [Cites] Mol Biol Cell. 1997 Feb;8(2):287-301 [9190208.001]
  • [Cites] J Biol Chem. 1997 May 9;272(19):12738-46 [9139732.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] Mol Cell Biol. 1997 Oct;17(10):5771-83 [9315635.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10699-704 [9380698.001]
  • [Cites] Oncogene. 1997 Dec 4;15(23):2855-66 [9419977.001]
  • [Cites] Mol Cell Biol. 1998 Feb;18(2):753-61 [9447971.001]
  • [Cites] Carcinogenesis. 1998 May;19(5):765-9 [9635861.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10493-8 [9724731.001]
  • [Cites] J Biol Chem. 1999 Apr 2;274(14):9463-71 [10092628.001]
  • [Cites] Pediatr Res. 1999 May;45(5 Pt 1):692-6 [10231867.001]
  • [Cites] Cell. 1999 Sep 17;98(6):859-69 [10499802.001]
  • [Cites] Mol Cell. 2004 Dec 3;16(5):831-7 [15574337.001]
  • [Cites] J Biochem. 2005 Mar;137(3):381-6 [15809340.001]
  • [Cites] Cancer Cell. 2005 Jun;7(6):591-8 [15950907.001]
  • [Cites] Stem Cells. 2005 Aug;23(7):1002-11 [15941859.001]
  • [Cites] Nat Cell Biol. 2005 Aug;7(8):831-6 [16007079.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1400-6 [15878982.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1783-7 [16107892.001]
  • (PMID = 16936279.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Indoles; 0 / Multiprotein Complexes; 0 / Retinoblastoma-Like Protein p107; 114719-57-2 / fascaplysine; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
  • [Other-IDs] NLM/ PMC1698824
  •  go-up   go-down


78. Rimando MG, Chua MN, Yuson Ed, de Castro-Bernas G, Okamoto T: Prevalence of GSTT1, GSTM1 and NQO1 (609C&gt;T) in Filipino children with ALL (acute lymphoblastic leukaemia). Biosci Rep; 2008 Jun;28(3):117-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of GSTT1, GSTM1 and NQO1 (609C>T) in Filipino children with ALL (acute lymphoblastic leukaemia).
  • In the present paper, we examined the incidence of polymorphic genes involved with the detoxification of exogenous chemicals, including carcinogens, namely GSTT1 (glutathione transferase theta1), GSTM1 (glutathione transferase micro1) and NQO1 (NAD(P)H:quinone oxidoreductase 1) in 60 Filipino paediatric patients with ALL (acute lymphoblastic leukaemia).
  • When these two genotypes, GSTM1 null and NQO1 C/C, were combined, the hazard rate for childhood leukaemia was significantly increased (P<0.001).
  • [MeSH-major] Glutathione Transferase / genetics. NAD(P)H Dehydrogenase (Quinone) / genetics. Neoplasm Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18444911.001).
  • [ISSN] 1573-4935
  • [Journal-full-title] Bioscience reports
  • [ISO-abbreviation] Biosci. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


79. Tassano E, Acquila M, Tavella E, Micalizzi C, Panarello C, Morerio C: MicroRNA-125b-1 and BLID upregulation resulting from a novel IGH translocation in childhood B-Cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer; 2010 Aug;49(8):682-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA-125b-1 and BLID upregulation resulting from a novel IGH translocation in childhood B-Cell precursor acute lymphoblastic leukemia.
  • Recent findings have also revealed their significant role in B-cell precursor acute lymphoblastic leukemia.
  • In this study, we describe a pediatric case of B-cell precursor acute lymphoblastic leukemia showing microRNA-125b-1 (MIR125B1) and BLID gene overexpression, resulting from a novel t(11;14)(q24.1;q32) translocation involving IGH.
  • [MeSH-major] BRCA2 Protein / genetics. Immunoglobulin Heavy Chains / genetics. MicroRNAs / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Acute Disease. Apoptosis Regulatory Proteins. Child. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 14 / genetics. Female. Humans. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20544842.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BLID protein, human; 0 / BRCA2 Protein; 0 / BRCA2 protein, human; 0 / Immunoglobulin Heavy Chains; 0 / MIRN125 microRNA, human; 0 / MicroRNAs; 0 / RNA, Messenger
  •  go-up   go-down


80. Hesson LB, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, Chiaramonte R, Griffiths M, Chalmers AD, Maher ER, Latif F: The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer; 2009 Jul 01;8:42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias.
  • We also determined the methylation status of CpG islands associated with RASSF1-10 in a series of childhood acute lymphocytic leukaemias (ALL) and normal blood and bone marrow samples.
  • These data show epigenetic inactivation of the candidate TSGs RASSF6 and RASSF10 is an extremely frequent event in the pathogenesis of childhood leukaemia.
  • [MeSH-major] Genes, Tumor Suppressor. Monomeric GTP-Binding Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Biol. 2002 Feb 19;12(4):253-65 [11864565.001]
  • [Cites] Biochim Biophys Acta. 2009 Dec;1796(2):114-28 [19344752.001]
  • [Cites] Oncogene. 2004 Mar 25;23(13):2408-19 [14743209.001]
  • [Cites] Biochem J. 2004 Jul 15;381(Pt 2):453-62 [15109305.001]
  • [Cites] Cell. 1986 Jan 31;44(2):283-92 [3943125.001]
  • [Cites] Mamm Genome. 1996 Aug;7(8):563-74 [8679005.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8688-93 [15574778.001]
  • [Cites] Science. 2004 Dec 24;306(5705):2267-70 [15618521.001]
  • [Cites] Leukemia. 2005 Mar;19(3):415-9 [15674422.001]
  • [Cites] Dev Cell. 2005 Mar;8(3):413-25 [15737936.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3497-508 [15867337.001]
  • [Cites] Oncogene. 2005 Jun 2;24(24):3987-94 [15806169.001]
  • [Cites] Mol Cell. 2005 Jun 10;18(6):637-50 [15949439.001]
  • [Cites] Nat Genet. 2005 Dec;37(12):1323-32 [16311596.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):950-6 [16404744.001]
  • [Cites] J Biol Chem. 2006 Feb 24;281(8):4557-63 [16344548.001]
  • [Cites] Dis Markers. 2007;23(1-2):73-87 [17325427.001]
  • [Cites] Exp Cell Res. 2007 Apr 15;313(7):1484-95 [17367779.001]
  • [Cites] Biochim Biophys Acta. 2007 Sep;1776(1):58-85 [17692468.001]
  • [Cites] Oncogene. 2007 Sep 13;26(42):6203-11 [17404571.001]
  • [Cites] Mol Cell. 2007 Sep 21;27(6):962-75 [17889669.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):26-33 [17910045.001]
  • [Cites] Mol Biol Cell. 2008 Apr;19(4):1772-82 [18272789.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):11-22 [12509763.001]
  • (PMID = 19570220.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G120/844
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RASSF6 protein, human; EC 3.6.5.2 / Monomeric GTP-Binding Proteins
  • [Other-IDs] NLM/ PMC2711046
  •  go-up   go-down


81. Tedeschi R, Luostarinen T, Marus A, Bzhalava D, Ogmundsdottir HM, Dillner J, De Paoli P, Surcel HM, Pukkala E, Lehtinen M, Lehtinen T: No risk of maternal EBV infection for childhood leukemia. Cancer Epidemiol Biomarkers Prev; 2009 Oct;18(10):2790-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No risk of maternal EBV infection for childhood leukemia.
  • We performed a large nested case-control study within the Finnish and Icelandic maternity cohorts to verify/falsify the association of maternal EBV infection with an increased risk of acute lymphoblastic leukemia (ALL) in the offspring found in previous studies.
  • All hematologic malignancies diagnosed among children born during 1983 to 2006 in Finland and 1997 to 2005 in Iceland were identified through national cancer registries.
  • For each index mother of a leukemia case, three matched control mothers with cancer-free offspring were identified.
  • First trimester sera from 561 ALL and 144 non-ALL index mothers and from 2,105 control mothers were analyzed for antibodies to EBV viral capsid antigen (IgG and IgM), early antigen (IgG) and ZEBRA protein (IgG).
  • [MeSH-major] Epstein-Barr Virus Infections / epidemiology. Herpesvirus 4, Human / isolation & purification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / virology. Pregnancy Complications, Infectious / epidemiology. Pregnancy Complications, Infectious / virology

  • MedlinePlus Health Information. consumer health - Infections and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755652.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Capsid Proteins; 0 / Epstein-Barr viral capsid antigen
  •  go-up   go-down


82. Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, Benetello A, Buldini B, Maglia O, Masera G, Conter V, Arico M, Biondi A, Gaipa G: Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol; 2009 Nov 1;27(31):5168-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
  • PURPOSE: Speed of blast clearance is an indicator of outcome in childhood acute lymphoblastic leukemia (ALL).
  • Cells were analyzed by four-color FCM for detection of leukemia-associated immunophenotypes.
  • [MeSH-major] Neoplasm, Residual / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology


83. Feltbower RG, Manda SO, Gilthorpe MS, Greaves MF, Parslow RC, Kinsey SE, Bodansky HJ, McKinney PA: Detecting small-area similarities in the epidemiology of childhood acute lymphoblastic leukemia and diabetes mellitus, type 1: a Bayesian approach. Am J Epidemiol; 2005 Jun 15;161(12):1168-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detecting small-area similarities in the epidemiology of childhood acute lymphoblastic leukemia and diabetes mellitus, type 1: a Bayesian approach.
  • Childhood acute lymphoblastic leukemia and diabetes mellitus, type 1, have common epidemiologic and etiologic features, including correlated international incidence and associations with infections.
  • Details of 299 children (0-14 years) with acute lymphoblastic leukemia and 1,551 children with diabetes diagnosed between 1986 and 1998 were extracted from two registers in Yorkshire, United Kingdom.
  • The links between diabetes and acute lymphoblastic leukemia observed for large regions are weaker for small areas.
  • [MeSH-major] Diabetes Mellitus, Type 1 / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology


84. Dincaslan HU, Yavuz G, Unal E, Tacyildiz N, Ikinciogullari A, Dogu F, Guloglu D, Yuksek N, Ertem U: Does serum soluble vascular endothelial growth factor levels have different importance in pediatric acute leukemia and malignant lymphoma patients? Pediatr Hematol Oncol; 2010 Oct;27(7):503-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does serum soluble vascular endothelial growth factor levels have different importance in pediatric acute leukemia and malignant lymphoma patients?
  • Vascular endothelial growth factor (VEGF) seems to play a central role in angiogenesis-lymphangiogenesis in hematological malignancies.
  • There are limited data related to childhood hematologic malignancies.
  • The aim of the study was to evaluate soluble VEGF (sVEGF) levels in children with acute leukemia and malignant lymphoma (ML) at diagnosis and in remission.
  • The levels of serum sVEGF were measured by enzyme-linked immunosorbent assay (ELISA) in 20 children with acute leukemia, 33 children with different histopathological subtypes of ML, and 20 healthy controls.
  • The levels of sVEGF at diagnosis (range 2 -1040 pg/mL; median 52 pg/mL) was significantly lower than in remission (range 136 -1960 pg/mL; median 630 pg/mL) in acute myeloid leukemia (AML) group (P = .018).
  • The sVEGF levels at diagnosis (range: 2 -640 pg/mL; median 89 pg/mL) was significantly lower compared to remission values (range: 116 -1960 pg/mL; median 136 pg/mL) in patients with acute lymphoblastic leukemia (ALL) (P = .002).
  • In ML group, including Burkitt's lymphoma (BL), T-cell non-Hodgkin's lymphoma (NHL), and Hodgkin's lymphoma (HL), sVEGF levels at diagnosis were higher than remission levels, but there was no statistically significant difference (P >.05).
  • On the other hand, there were significant difference between levels in active disease and control group, ie, BL versus control, T-cell NHL versus control, and HL versus control (P = .008, P = .043, P = .007, respectively).
  • The authors noticed that sVEGF levels showed distinct behavioral pattern in different childhood malignancies at diagnosis and in remission.
  • In acute leukemia and ML patients, VEGF acts through different pathophysiological mechanisms, in both bone marrow (BM) angiogenesis and lymphoid tissue lymphangiogenesis.
  • [MeSH-major] Hodgkin Disease / blood. Leukemia, Myeloid, Acute / blood. Lymphoma, Non-Hodgkin / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Vascular Endothelial Growth Factors / blood

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677920.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factors
  •  go-up   go-down


85. Robien K, Ness KK, Klesges LM, Baker KS, Gurney JG: Poor adherence to dietary guidelines among adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2008 Nov;30(11):815-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor adherence to dietary guidelines among adult survivors of childhood acute lymphoblastic leukemia.
  • Recent studies indicate that survivors of childhood acute lymphoblastic leukemia (ALL) are at increased risk of obesity and cardiovascular disease, conditions that healthy dietary patterns may help ameliorate or prevent.
  • To evaluate the usual dietary intake of adult survivors of childhood ALL, food frequency questionnaire data were collected from 72 participants, and compared with the 2007 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Cancer Prevention recommendations, the Dietary Approaches to Stop Hypertension (DASH) diet, and the 2005 United States Department of Agriculture (USDA) Food Guide.
  • These findings suggest that dietary intake for many adult survivors of childhood ALL is not concordant with dietary recommendations that may help reduce their risk of obesity, cardiovascular disease, or other treatment-related late effects.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1089-99 [11744511.001]
  • [Cites] Eur J Cancer Care (Engl). 2001 Mar;10(1):12-20 [11827263.001]
  • [Cites] J Am Diet Assoc. 2002 Feb;102(2):212-25 [11846115.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] JAMA. 2002 Apr 10;287(14):1832-9 [11939869.001]
  • [Cites] J Am Diet Assoc. 2002 Jun;102(6):801-8 [12067045.001]
  • [Cites] Br J Cancer. 2002 Nov 18;87(11):1204-9 [12439706.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):189-96 [12525509.001]
  • [Cites] J Am Diet Assoc. 2003 Mar;103(3):323-8 [12616253.001]
  • [Cites] Int J Epidemiol. 2003 Dec;32(6):1054-62 [14681273.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):631-40 [14745882.001]
  • [Cites] J Am Diet Assoc. 2004 Apr;104(4):615-35 [15054348.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1114-20 [15247121.001]
  • [Cites] Psychooncology. 2004 Sep;13(9):619-29 [15334530.001]
  • [Cites] J Am Diet Assoc. 2004 Oct;104(10):1561-8 [15389414.001]
  • [Cites] Med Pediatr Oncol. 1995 Sep;25(3):159-65 [7623724.001]
  • [Cites] N Engl J Med. 1997 Apr 17;336(16):1117-24 [9099655.001]
  • [Cites] J Natl Cancer Inst. 1998 Feb 4;90(3):219-25 [9462679.001]
  • [Cites] Obes Res. 1998 Sep;6 Suppl 2:51S-209S [9813653.001]
  • [Cites] Med Pediatr Oncol. 1999 Jul;33(1):60-3 [10401499.001]
  • [Cites] Cancer. 2005 May 15;103(10):2171-80 [15812823.001]
  • [Cites] Oncology (Williston Park). 2005 Jun;19(7):871-81; discussion 881-2, 885-6 [16053036.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5814-30 [16043830.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6499-507 [16170159.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2826-8 [16364996.001]
  • [Cites] Eur J Clin Nutr. 2006 Sep;60(9):1046-54 [16482067.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1303-12 [16894525.001]
  • [Cites] J Am Coll Nutr. 2006 Oct;25(5):370-81 [17031005.001]
  • [Cites] CA Cancer J Clin. 2006 Nov-Dec;56(6):323-53 [17135691.001]
  • [Cites] Am J Hypertens. 2007 Mar;20(3):225-32 [17324731.001]
  • [Cites] J Nutr. 2007 Nov;137(11):2443-50 [17951483.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1115-26 [12569614.001]
  • (PMID = 18989158.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000400; United States / NCI NIH HHS / CA / U24 CA055727; United States / NCRR NIH HHS / RR / M01-RR00400; United States / NCI NIH HHS / CA / K23 CA085503; United States / NCI NIH HHS / CA / R21 CA106778; United States / NCI NIH HHS / CA / R21-CA106778; United States / NCI NIH HHS / CA / K23-CA85503; United States / NCI NIH HHS / CA / U24-CA55727; United States / NCI NIH HHS / CA / CA106778-02; United States / NCI NIH HHS / CA / R21 CA106778-02
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS87238; NLM/ PMC2633871
  •  go-up   go-down


86. Sengupta TK, Leclerc GM, Hsieh-Kinser TT, Leclerc GJ, Singh I, Barredo JC: Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer; 2007 Jul 10;6:46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
  • BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy affecting children.
  • The aim of this study was to investigate the AMP activated protein kinase (AMPK) as a potential target in childhood acute lymphoblastic leukemia (ALL) subtypes characterized by non-random translocation signature profiles.
  • We evaluated the effects of the AMPK activator AICAR on cell growth, cell cycle regulators and apoptosis of various childhood ALL cells.
  • CONCLUSION: AICAR-mediated AMPK activation was found to be a proficient cytotoxic agent in ALL cells and the mechanism of its anti-proliferative and apoptotic effect appear to be mediated via activation of p38-MAPK pathway, increased expression of cell cycle inhibitory proteins p27 and p53, and downstream effects on the mTOR pathway, hence exhibiting therapeutic potential as a molecular target for the treatment of childhood ALL.
  • Therefore, activation of AMPK by AICAR represents a novel approach to targeted therapy, and suggests a role for AICAR in combination therapy with inhibitors of the PI3K/Akt/mTOR pathways for the treatment of childhood in ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2005 Dec 9;310(5754):1642-6 [16308421.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):298-306 [15549091.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Cell. 2006 Feb 10;124(3):471-84 [16469695.001]
  • [Cites] Dev Cell. 2006 May;10(5):549-61 [16678772.001]
  • [Cites] BMC Cancer. 2006;6:132 [16707018.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:133-41 [17124052.001]
  • [Cites] Circ Res. 2000 May 26;86(10):1069-77 [10827137.001]
  • [Cites] Hum Mol Genet. 2000 Jul 22;9(12):1721-7 [10915759.001]
  • [Cites] Biochem J. 2000 Oct 1;351(Pt 1):95-105 [10998351.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Sep 21;287(2):562-7 [11554766.001]
  • [Cites] BMJ. 2002 Feb 2;324(7332):283-7 [11823363.001]
  • [Cites] Science. 2002 Feb 15;295(5558):1291-4 [11847341.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):23977-80 [11997383.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Oncology. 2004;67(5-6):476-9 [15714005.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2441-8 [15781660.001]
  • [Cites] Mol Cell. 2005 Apr 29;18(3):283-93 [15866171.001]
  • [Cites] Hum Mol Genet. 2005 May 15;14(10):1283-92 [15800014.001]
  • [Cites] Circ Res. 2005 Oct 14;97(8):837-44 [16151020.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7475-81 [16288294.001]
  • [Cites] J Biol Chem. 2005 Nov 25;280(47):39582-93 [16176927.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25226-32 [11994296.001]
  • [Cites] Oncogene. 2002 Sep 5;21(39):6082-90 [12203120.001]
  • [Cites] FEBS Lett. 2002 Aug 28;526(1-3):38-42 [12208500.001]
  • [Cites] Science. 2002 Nov 15;298(5597):1435-8 [12364621.001]
  • [Cites] Biochem Soc Trans. 2003 Feb;31(Pt 1):162-8 [12546677.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1382-8 [12649203.001]
  • [Cites] Leukemia. 2003 Apr;17(4):700-6 [12682627.001]
  • [Cites] J Mol Endocrinol. 2003 Apr;30(2):151-61 [12683939.001]
  • [Cites] FEBS Lett. 2003 Jul 3;546(1):113-20 [12829246.001]
  • [Cites] J Biol Chem. 2003 Aug 1;278(31):28434-42 [12764152.001]
  • [Cites] Genes Dev. 2003 Aug 15;17(16):1969-78 [12893778.001]
  • [Cites] Cancer Cell. 2003 Oct;4(4):257-62 [14585353.001]
  • [Cites] Curr Biol. 2003 Nov 11;13(22):2004-8 [14614828.001]
  • [Cites] Cell. 2003 Nov 26;115(5):577-90 [14651849.001]
  • [Cites] Trends Biochem Sci. 2004 Jan;29(1):32-8 [14729330.001]
  • [Cites] J Biol. 2003;2(4):28 [14511394.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):91-9 [15261145.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Aug 13;321(1):161-7 [15358229.001]
  • [Cites] Eur J Biochem. 1989 Dec 8;186(1-2):123-8 [2574667.001]
  • [Cites] FEBS Lett. 1994 Oct 10;353(1):33-6 [7926017.001]
  • [Cites] Eur J Biochem. 1995 Apr 15;229(2):558-65 [7744080.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Jun;277(3):1397-401 [8667202.001]
  • [Cites] Eur J Biochem. 1997 Jun 1;246(2):259-73 [9208914.001]
  • [Cites] FEBS Lett. 1997 Jun 16;409(3):452-6 [9224708.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Dec;20(4):392-8 [9408756.001]
  • [Cites] Nat Genet. 1998 Jan;18(1):38-43 [9425897.001]
  • [Cites] Nature. 1998 Jan 8;391(6663):184-7 [9428765.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Feb 24;243(3):821-6 [9500985.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):605-15 [9718381.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15653-8 [9861025.001]
  • [Cites] Curr Opin Pediatr. 1999 Feb;11(1):33-8 [10084082.001]
  • [Cites] Trends Biochem Sci. 1999 Jan;24(1):22-5 [10087918.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):48707-15 [15355997.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Feb 3;340(1):43-7 [16377306.001]
  • (PMID = 17623090.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098152; United States / NCI NIH HHS / CA / CA098152-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole; 0 / Antineoplastic Agents; 0 / Imidazoles; 0 / Multienzyme Complexes; 0 / Neoplasm Proteins; 0 / Prodrugs; 0 / Pyridines; 0 / Ribonucleotides; 24386-93-4 / 5-iodotubercidin; 360-97-4 / Aminoimidazole Carboxamide; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / AMP-Activated Protein Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; F0X88YW0YK / AICA ribonucleotide; M351LCX45Y / Tubercidin; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC1948012
  •  go-up   go-down


87. Paulsson K, Forestier E, Lilljebjörn H, Heldrup J, Behrendtz M, Young BD, Johansson B: Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A; 2010 Dec 14;107(50):21719-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia.
  • High hyperdiploid acute lymphoblastic leukemia (ALL) is one of the most common malignancies in children.
  • Other frequent abnormalities included whole-chromosome uniparental isodisomies (wUPIDs) 9 and 11, gain of 17q not associated with isochromosome formation, extra gain of part of 21q, deletions of ETS variant 6 (ETV6), cyclin-dependent kinase inhibitor 2A (CKDN2A) and paired box 5 (PAX5), and PAN3 poly(A) specific ribonuclease subunit homolog (PAN3) microdeletions.
  • Finally, two cases had partial deletions of AT rich interactive domain 5B (ARID5B), indicating that acquired as well as constitutional variants in this locus may be associated with pediatric ALL.
  • Here we provide a comprehensive characterization of the genetic landscape of high hyperdiploid childhood ALL, including the heterogeneous pattern of secondary genetic events.
  • [MeSH-major] Chromosome Aberrations. Diploidy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


88. Lazic J, Tosic N, Dokmanovic L, Krstovski N, Rodic P, Pavlovic S, Janic D: Clinical features of the most common fusion genes in childhood acute lymphoblastic leukemia. Med Oncol; 2010 Jun;27(2):449-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of the most common fusion genes in childhood acute lymphoblastic leukemia.
  • Contemporary protocols ensure high-remission rate and long-term free survival in children with acute lymphoblastic leukemia (ALL), but small percentage of patients is still incurable.
  • Our study enrolled 70 pediatric patients with de novo ALL, analyzed using reverse transcriptase-polymerase chain reaction for the presence of four major risk-stratifying translocations (BCR/ABL, MLL/AF4, TEL/AML1, and E2A/PBX1).
  • [MeSH-major] Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1999 Dec;13(12):1901-28 [10602411.001]
  • [Cites] Leukemia. 1995 Dec;9(12):1985-9 [8609706.001]
  • [Cites] Br J Haematol. 2000 Dec;111(4):1071-9 [11167742.001]
  • [Cites] Pediatr Blood Cancer. 2004 Mar;42(3):278-80 [14752867.001]
  • [Cites] Br J Haematol. 1999 Dec;107(3):667-9 [10583273.001]
  • [Cites] Blood. 2000 Apr 15;95(8):2659-65 [10753848.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):233-45 [17361217.001]
  • [Cites] Expert Opin Emerg Drugs. 2007 Mar;12(1):165-79 [17355221.001]
  • [Cites] Blood. 1991 Feb 1;77(3):440-7 [1991161.001]
  • [Cites] Leuk Res. 1998 Jan;22(1):77-80 [9585083.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15101-6 [12415113.001]
  • [Cites] Leuk Res. 1996 May;20(5):441-3 [8683984.001]
  • [Cites] Oncogene. 2004 May 24;23(24):4275-83 [15156184.001]
  • [Cites] Blood. 1998 Feb 1;91(3):1021-8 [9446665.001]
  • [Cites] Leuk Res. 2008 Oct;32(10):1518-22 [18455790.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Blood. 1997 Jul 15;90(2):571-7 [9226156.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1075-80 [8562932.001]
  • [Cites] Leukemia. 2007 Apr;21(4):642-6 [17287854.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Aug;29(8):585 [17762503.001]
  • [Cites] Leukemia. 1996 Jun;10(6):957-63 [8667652.001]
  • [Cites] Ann Hematol. 1998 Jul-Aug;77(1-2):55-9 [9760154.001]
  • [Cites] Med Pediatr Oncol. 1999 Jun;32(6):455-6 [10358709.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):489-500 [16098062.001]
  • (PMID = 19488866.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


89. Hepworth SJ, Feltbower RG, McKinney PA: Childhood leukaemias and CNS tumours: correlation of international incidence rates. Eur J Cancer; 2006 Mar;42(4):509-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood leukaemias and CNS tumours: correlation of international incidence rates.
  • Childhood leukaemia has a potential infectious aetiology whilst infections may also be linked to paediatric central nervous system (CNS) tumours.
  • Using data from 29 countries we investigated the correlation between international incidence rates of childhood leukaemia and CNS tumours, focusing on acute lymphoblastic leukaemia (ALL), astrocytoma and ependymoma-subtypes that are hypothesised to have an infectious aetiology.
  • National incidence rates of childhood ALL and astrocytomas were highly correlated and this may reflect a common environmental cause whose origin may be infectious in nature.
  • Variation in levels of ascertainment may partially explain this, although childhood environmental exposures related to infections will also be affected by levels of affluence.
  • [MeSH-major] Astrocytoma / epidemiology. Central Nervous System Neoplasms / epidemiology. Ependymoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410049.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


90. Gra OA, Glotov AS, Kozhekbaeva Zhm, Makarova OV, Nasedkina TV: [Genetic polymorphism in GST, NAT2, and MTRR and susceptibility to childhood acute leukemia]. Mol Biol (Mosk); 2008 Mar-Apr;42(2):214-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Genetic polymorphism in GST, NAT2, and MTRR and susceptibility to childhood acute leukemia].
  • In the present work the frequencies of xenobiotic-metabolizing gene polymorphisms in 332 children with the diagnosis acute lymphoblastic leukemia (ALL), 71 children with the diagnosis acute myeloblastic leukemia (AML) and 490 healthy donors have been determined using allele-specific hybridization on the biochip.
  • Statistically significant increase in the frequency of GSTT1 "null" genotype (OR = 1.9, p = 4.7E-5) and GSTT1/GSTM1 double "null" genotype (OR = 3.1, p = 2.5E-8) in children with acute leukemia relative to healthy donors group has been revealed.
  • Also 1.8-fold increase in the frequency of NAT2 genotype 341T/T, 481C/C, 590G/G in children with acute leukemia relative to healthy donors group (p = 0.026) has been recognized.
  • Analysis of gene-gene interactions has showed that in patients with acute leukemia genotype NAT2 341T/T, 481C/C, 590G/G in combination with GSTT1 "null" and/or GSTM1 "null" genotype is significantly more frequent than in population control.
  • Besides the reduction of MTRR genotype 66G/G frequency in girls with acute leukemia relative to female healthy donors has been found (OR = 0.50, p = 0.0015).
  • Analysis of gene-gene interactions has shown that the presence of GSTT1 "null" and/or GSTM1 "null" genotype in combination with MTRR genotype 66A/- may consider as risk factor of acute leukemia in girls.
  • Thus, the studied polymorphic variants of genes GSTT1, GSTM1, NAT2 and MTRR can modulate the risk of childhood acute leukemia, residents of European part of Russia.
  • [MeSH-major] Arylamine N-Acetyltransferase / genetics. Ferredoxin-NADP Reductase / genetics. Genetic Predisposition to Disease. Glutathione Transferase / genetics. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18610829.001).
  • [ISSN] 0026-8984
  • [Journal-full-title] Molekuliarnaia biologiia
  • [ISO-abbreviation] Mol. Biol. (Mosk.)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] EC 1.18.1.- / methionine synthase reductase; EC 1.18.1.2 / Ferredoxin-NADP Reductase; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / NAT2 protein, human; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


91. Liu JY, Li ZG, Gao C, Cui L, Wu MY: [Characteristics of T cell receptor beta gene rearrangements and its role in minimal residual disease detection in childhood T-cell acute lymphoblastic leukemia]. Zhonghua Er Ke Za Zhi; 2008 Jul;46(7):487-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristics of T cell receptor beta gene rearrangements and its role in minimal residual disease detection in childhood T-cell acute lymphoblastic leukemia].
  • OBJECTIVE: To explore the characteristics of T cell receptor beta (TCRbeta) gene rearrangements in children with T-cell acute lymphoblastic leukemia (T-ALL) and establish a system of quantitative detection of MRD with real-time quantitative (RQ-PCR) targeted at TCRbeta gene rearrangement.
  • RESULTS: Clonal rearrangements were identified in 92.3% childhood T-ALL (Vbeta-Dbeta-Jbeta rearrangements in 84.6%, Dbeta-Jbeta rearrangements in 50%).
  • The segment Jbeta2.7 in childhood T-ALL was preferentially used.
  • [MeSH-major] Gene Rearrangement, beta-Chain T-Cell Antigen Receptor / genetics. Neoplasm, Residual / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19099802.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


92. Remke M, Pfister S, Kox C, Toedt G, Becker N, Benner A, Werft W, Breit S, Liu S, Engel F, Wittmann A, Zimmermann M, Stanulla M, Schrappe M, Ludwig WD, Bartram CR, Radlwimmer B, Muckenthaler MU, Lichter P, Kulozik AE: High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. Blood; 2009 Jul 30;114(5):1053-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response.
  • Precursor T-cell acute lymphoblastic leukemia (T-ALL) in children represents a clinical challenge, because relapses are usually fatal.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Deletion. Chromosomes, Human, Pair 6 / genetics. Neoplasm Proteins / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Signal Transduction / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19406988.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GPL5713/ GSE8738
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / NOTCH1 protein, human; 0 / Neoplasm Proteins; 0 / Receptor, Notch1; 0 / Transforming Growth Factor beta; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


93. Gudowius S, Recker K, Laws HJ, Dirksen U, Tröger A, Wieczorek U, Furlan S, Göbel U, Hanenberg H: Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL. Klin Padiatr; 2006 Nov-Dec;218(6):327-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL.
  • BACKGROUND: Contemporary risk adapted treatment protocols for childhood acute lymphoblastic leukemia (ALL) rely on accurate risk assessment strategies for disease re-occurrence by incorporating clinical parameters as well as immunological, molecular and cytogenetic features of the blasts at initial manifestation.
  • Other myeloid antigens (CD13, CD14, CD15, CD65) were positive on blasts in < 25 % of patients.
  • CONCLUSIONS: These analyses clearly identified the three antigens CD19, CD22 and HLA-DR present on blasts in more than 90 % of patients as potential target structures for targeted therapies with native or toxin-bound monoclonal antibodies in childhood ALL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD19 / analysis. Burkitt Lymphoma / immunology. HLA-DR Antigens / analysis. Immunotherapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Sialic Acid Binding Ig-like Lectin 2 / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17080335.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD19; 0 / HLA-DR Antigens; 0 / Sialic Acid Binding Ig-like Lectin 2
  •  go-up   go-down


94. Kroll ME, Draper GJ, Stiller CA, Murphy MF: Childhood leukemia incidence in Britain, 1974-2000: time trends and possible relation to influenza epidemics. J Natl Cancer Inst; 2006 Mar 15;98(6):417-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood leukemia incidence in Britain, 1974-2000: time trends and possible relation to influenza epidemics.
  • We investigated time trends in childhood leukemia by using Poisson regression methods to analyze data from the National Registry of Childhood Tumours, a long-standing high-quality registry that covers the whole childhood population of Britain.
  • During 1974-2000, the average annual percentage change in rate (AAC) of childhood acute lymphoblastic leukemia (ALL) in Britain was 0.7% (95% confidence interval [CI] = 0.4 to 1.0).
  • There was no statistically significant time trend in other subtypes of ALL combined (1980-1996) or in acute myeloid leukemia (1974-2000).
  • These results are consistent with hypotheses that some childhood leukemia may be triggered by infection occurring close to the time of diagnosis of leukemia, particularly in conditions of low herd immunity, and raise the possibility that contact with influenza shortly before the diagnosis of leukemia may sometimes be involved.
  • [MeSH-major] Disease Outbreaks. Influenza, Human / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / virology

  • MedlinePlus Health Information. consumer health - Flu.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2006 Dec 6;98(23):1746; author reply 1746-7 [17148778.001]
  • (PMID = 16537835.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


95. Linabery AM, Blair CK, Gamis AS, Olshan AF, Heerema NA, Ross JA: Congenital abnormalities and acute leukemia among children with Down syndrome: a Children's Oncology Group study. Cancer Epidemiol Biomarkers Prev; 2008 Oct;17(10):2572-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital abnormalities and acute leukemia among children with Down syndrome: a Children's Oncology Group study.
  • Children with Down syndrome, due to their heightened risk of leukemia and increased prevalence of congenital abnormalities, comprise a valuable population in which to study etiology.
  • A Children's Oncology Group study investigated the causes of childhood leukemia in children with Down syndrome diagnosed at ages 0 to 19 years during the period 1997-2002.
  • Telephone interviews were completed with mothers of 158 cases [n=97 acute lymphoblastic leukemia (ALL) and n=61 acute myeloid leukemia (AML)] and 173 controls.
  • Odds ratios (OR) and 95% confidence intervals (95% CI) were computed via unconditional logistic regression to evaluate the association between congenital abnormalities and acute leukemia overall, and ALL and AML analyzed separately.
  • The results do not provide evidence for an association among the index children (OR(Combined), 0.74; 95% CI, 0.45-1.23; OR(ALL), 0.67; 95% CI, 0.38-1.20; OR(AML),1.03; 95% CI, 0.49-2.16) or their siblings (OR(Combined), 1.23; 95% CI, 0.71-2.13; OR(ALL), 1.12; 95% CI, 0.60-2.09; OR(AML), 1.60; 95% CI, 0.66-3.86), suggesting congenital malformations do not confer additional risk of leukemia beyond the risk attributable to trisomy 21 in this population.

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Birth Defects.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Hematol Oncol. 1987;4(3):211-30 [2978961.001]
  • [Cites] Am J Hum Genet. 1990 Mar;46(3):478-85 [2309699.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Mar-Apr;23(3):175-8 [11305722.001]
  • [Cites] Int J Epidemiol. 2001 Apr;30(2):350-2 [11369741.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2001 Dec 1;61(3):199-205 [11700189.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1339-45 [12599243.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):162-74 [15313588.001]
  • [Cites] Cancer Res. 1991 Jul 15;51(14):3696-701 [2065325.001]
  • [Cites] Leukemia. 1992;6 Suppl 1:5-7 [1532221.001]
  • [Cites] Am J Epidemiol. 1993 Mar 15;137(6):629-38 [8470664.001]
  • [Cites] Br J Cancer. 1993 Aug;68(2):357-63 [8347491.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):201-7 [8630931.001]
  • [Cites] Am J Hum Genet. 1997 Mar;60(3):474-85 [9042906.001]
  • [Cites] Am J Med Genet. 1998 Jan 6;75(1):22-7 [9450852.001]
  • [Cites] Am J Med Genet. 1998 Jun 5;77(5):431-8 [9632176.001]
  • [Cites] Br J Cancer. 1998 Nov;78(9):1244-9 [9820188.001]
  • [Cites] J Pediatr. 1998 Nov;133(5):617-23 [9821417.001]
  • [Cites] Arch Dis Child. 1999 Jan;80(1):1-3 [10325750.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):8-12 [15390275.001]
  • [Cites] Cancer. 2005 May 1;103(9):1939-48 [15770693.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):405-10 [15952191.001]
  • [Cites] J Pediatr Health Care. 2006 Jan-Feb;20(1):47-54 [16399479.001]
  • [Cites] Nature. 2006 Jun 1;441(7093):595-600 [16554754.001]
  • [Cites] Pediatrics. 2006 Nov;118(5):e1499-508 [17030598.001]
  • [Cites] Curr Opin Pediatr. 2007 Feb;19(1):9-14 [17224656.001]
  • [Cites] JAMA. 2008 Jan 2;299(1):61-9 [18167407.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):500-6 [18296646.001]
  • [Cites] Lancet. 1981 Nov 7;2(8254):1020-2 [6118480.001]
  • [Cites] Dev Med Child Neurol. 1982 Dec;24(6):817-29 [6218002.001]
  • [Cites] Lancet. 2000 Jan 15;355(9199):165-9 [10675114.001]
  • (PMID = 18829445.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA016086-259036; United States / NIEHS NIH HHS / ES / P30 ES10126; United States / NCI NIH HHS / CA / T32 CA099936-01A1; United States / NIEHS NIH HHS / ES / P30 ES010126; United States / NCI NIH HHS / CA / R01 CA075169-03; United States / NCI NIH HHS / CA / P30 CA016086; United States / NCI NIH HHS / CA / R01 CA075169; United States / NCI NIH HHS / CA / R01 CA75169; United States / NCI NIH HHS / CA / CA075169-03; United States / NCI NIH HHS / CA / T32 CA099936; United States / NCI NIH HHS / CA / P30 CA016086-259036; United States / NCI NIH HHS / CA / CA099936-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS78459; NLM/ PMC2610427
  •  go-up   go-down


96. Pui CH: Recent research advances in childhood acute lymphoblastic leukemia. J Formos Med Assoc; 2010 Nov;109(11):777-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent research advances in childhood acute lymphoblastic leukemia.
  • Recent progress in risk-adapted treatment for childhood acute lymphoblastic leukemia has secured 5-year event-free survival rates of approximately 80% and 5-year survival rates approaching 90%.
  • As high-resolution, genome-wide analyses of leukemic and normal host cells continue to identify novel subtypes of lymphoblastic leukemia and provide new insights into leukemogenesis, we can look forward to the time when all cases of this disease will be classified according to specific genetic abnormalities, some of which will yield "druggable" targets for more effective and less toxic treatments.
  • Meanwhile, it is sobering to consider that a significant fraction of leukemia survivors will develop serious health problems within 30 years of their initial diagnosis.
  • The ultimate challenge is to gain a clear understanding of the factors that give rise to childhood leukemia in the first place, and enable preventive strategies to be devised and implemented.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Formosan Medical Association & Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 21126650.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Singapore
  •  go-up   go-down


97. Ripert M, Menegaux F, Perel Y, Méchinaud F, Plouvier E, Gandemer V, Lutz P, Vannier JP, Lamagnére JP, Margueritte G, Boutard P, Robert A, Armari-Alla C, Munzer M, Millot F, de Lumley L, Berthou C, Rialland X, Pautard B, Clavel J: Familial history of cancer and childhood acute leukemia: a French population-based case-control study. Eur J Cancer Prev; 2007 Oct;16(5):466-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial history of cancer and childhood acute leukemia: a French population-based case-control study.
  • A case-control study was conducted to investigate the role of a familial history of cancer in the etiology of childhood acute leukemia.
  • A familial history of solid tumor in first or second-degree relatives was associated with an increased risk of acute lymphoblastic leukemia (odds ratio (OR)=1.6 [95% confidence interval, 1.2-2.1]), while a familial history of hematopoietic malignancies in first or second-degree relatives was associated with an increased risk of acute myeloid leukemia (OR=4.3 [1.4-13]).
  • Significant associations between childhood acute leukemia and familial history of genital cancers and brain tumor were also observed (OR=2.7 [1.2-5.8] and OR=10.7 [1.3-86], respectively).
  • This study supports the hypothesis that a familial history of cancer may play a role in the etiology of childhood acute leukemia.
  • [MeSH-major] Leukemia / genetics. Neoplasms / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Case-Control Studies. Child. Child, Preschool. Family. Female. Humans. Infant. Infant, Newborn. Male

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):712-7 [10597183.001]
  • [Cites] Br J Cancer. 2005 Nov 28;93(11):1307-9 [16288301.001]
  • [Cites] Lancet. 2001 Sep 1;358(9283):711-7 [11551577.001]
  • [Cites] Cancer Causes Control. 2001 Dec;12(10):935-41 [11808713.001]
  • [Cites] Int J Cancer. 2003 Aug 20;106(2):252-9 [12800202.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):139-45 [14710221.001]
  • [Cites] Cancer Detect Prev. 2004;28(2):83-7 [15068830.001]
  • [Cites] Eur J Cancer Prev. 2004 Apr;13(2):97-103 [15100575.001]
  • [Cites] Scand J Haematol. 1975 Sep;15(2):117-31 [1188315.001]
  • [Cites] J Natl Cancer Inst. 1978 Jun;60(6):1243-50 [274587.001]
  • [Cites] Am J Epidemiol. 1989 Oct;130(4):655-64 [2773914.001]
  • [Cites] N Engl J Med. 1995 Dec 14;333(24):1594-9 [7477194.001]
  • [Cites] Am J Hematol. 1996 Aug;52(4):295-304 [8701948.001]
  • [Cites] Cancer Causes Control. 1998 Mar;9(2):161-71 [9578293.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):990-3 [11286482.001]
  • (PMID = 17923819.001).
  • [ISSN] 0959-8278
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ HALMS207608; NLM/ PMC2596893
  •  go-up   go-down


98. Reid AG, Seppa L, von der Weid N, Niggli FK, Betts DR: A t(12;17)(p13;q12) identifies a distinct TEL rearrangement-negative subtype of precursor-B acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2006 Feb;165(1):64-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A t(12;17)(p13;q12) identifies a distinct TEL rearrangement-negative subtype of precursor-B acute lymphoblastic leukemia.
  • Structural rearrangements involving the short arm of chromosome 12 are common in acute lymphoblastic leukemia (ALL) and often involve the TEL locus at 12p13.
  • We identified a t(12;17) in 2 of 398 childhood ALL patients karyotyped at presentation in our institute.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16490598.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / ETS translocation variant 6 protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


99. Dockerty JD, Herbison P, Skegg DC, Elwood M: Vitamin and mineral supplements in pregnancy and the risk of childhood acute lymphoblastic leukaemia: a case-control study. BMC Public Health; 2007;7:136
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin and mineral supplements in pregnancy and the risk of childhood acute lymphoblastic leukaemia: a case-control study.
  • BACKGROUND: An earlier case-control study from Western Australia reported a protective effect of maternal folic acid supplementation during pregnancy on the risk of childhood acute lymphoblastic leukaemia (ALL).
  • RESULTS: There was no association between reported folate intake during pregnancy and childhood ALL (adjusted odds ratio (OR) 1.1, 95% confidence interval (CI) 0.5-2.7).
  • CONCLUSION: Our own study, of similar size to the Australian study, does not support the hypothesis of a protective effect of folate on childhood ALL.
  • [MeSH-major] Dietary Supplements / utilization. Folic Acid / therapeutic use. Iron, Dietary / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2004 Aug;15(6):559-70 [15280635.001]
  • [Cites] Br J Cancer. 1996 May;73(9):1141-7 [8624278.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1483-9 [10424755.001]
  • [Cites] Birth Defects Res A Clin Mol Teratol. 2004 Nov;70(11):842-3 [15523662.001]
  • [Cites] Cancer Causes Control. 2004 Nov;15(9):931-7 [15577295.001]
  • [Cites] Haematologica. 2004 Feb;89(2):139-44 [15003888.001]
  • [Cites] Am J Epidemiol. 2007 Jan 1;165(1):27-35 [17035343.001]
  • [Cites] Lancet. 1999 Dec 4;354(9194):1967-8 [10622301.001]
  • [Cites] Lancet. 2001 Dec 8;358(9297):1935-40 [11747917.001]
  • [Cites] N Z Med J. 2003 Jan 24;116(1168):U303 [12601426.001]
  • [Cites] Am J Epidemiol. 2003 Apr 1;157(7):571-82 [12672676.001]
  • [Cites] BMC Med Genet. 2005 May 27;6:23 [15921520.001]
  • (PMID = 17605825.001).
  • [ISSN] 1471-2458
  • [Journal-full-title] BMC public health
  • [ISO-abbreviation] BMC Public Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iron, Dietary; 0 / Minerals; 0 / Vitamins; 935E97BOY8 / Folic Acid
  • [Other-IDs] NLM/ PMC1925082
  •  go-up   go-down


100.